<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Intensive Care</journal-id><journal-id journal-id-type="iso-abbrev">Ann Intensive Care</journal-id><journal-title-group><journal-title>Annals of Intensive Care</journal-title></journal-title-group><issn pub-type="epub">2110-5820</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40394364</article-id><article-id pub-id-type="pmc">PMC12092332</article-id>
<article-id pub-id-type="publisher-id">1464</article-id><article-id pub-id-type="doi">10.1186/s13613-025-01464-w</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Critical insights for intensivists on Guillain-Barr&#x000e9; syndrome</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5155-196X</contrib-id><name><surname>Weiss</surname><given-names>Nicolas</given-names></name><address><email>nicolas.weiss@aphp.fr</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Marois</surname><given-names>Cl&#x000e9;mence</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Le Guennec</surname><given-names>Loic</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Rohaut</surname><given-names>Benjamin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Demeret</surname><given-names>Sophie</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02mh9a093</institution-id><institution-id institution-id-type="GRID">grid.411439.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2150 9058</institution-id><institution>D&#x000e9;partement de neurologie, Service de M&#x000e9;decine Intensive R&#x000e9;animation &#x000e0; orientation neurologique, </institution><institution>Sorbonne Universit&#x000e9;, AP-HP.Sorbonne Universit&#x000e9;, H&#x000f4;pital de la Piti&#x000e9;-Salp&#x000ea;tri&#x000e8;re, </institution></institution-wrap>47-83, boulevard de l&#x02019;h&#x000f4;pital, Paris, 75013 France </aff><aff id="Aff2"><label>2</label>Brain Liver Piti&#x000e9;-Salp&#x000ea;tri&#x000e8;re (BLIPS) Study Group, Centre de recherche Saint- Antoine, Maladies m&#x000e9;taboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN), INSERM UMR_S 938, Paris, France </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02en5vm52</institution-id><institution-id institution-id-type="GRID">grid.462844.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 2308 1657</institution-id><institution>Groupe de Recherche Clinique en REanimation et Soins intensifs du Patient en Insuffisance Respiratoire aiguE (GRC-RESPIRE) Sorbonne Universit&#x000e9;, </institution></institution-wrap>Paris, France </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/051sk4035</institution-id><institution-id institution-id-type="GRID">grid.462098.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 0643 431X</institution-id><institution>Institut Cochin, Leukemia and Niche Dynamics Laboratory, </institution><institution>Universit&#x000e9; Paris Cit&#x000e9;, INSERM, CNRS, </institution></institution-wrap>Paris, France </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02vjkv261</institution-id><institution-id institution-id-type="GRID">grid.7429.8</institution-id><institution-id institution-id-type="ISNI">0000000121866389</institution-id><institution>Paris Brain Institute - ICM, Inserm, CNRS, PICNIC-Lab, </institution></institution-wrap>Paris, France </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><elocation-id>67</elocation-id><history><date date-type="received"><day>30</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>14</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Guillain-Barr&#x000e9; Syndrome (GBS) is a leading cause of acute flaccid tetraplegia worldwide, with an incidence of 1&#x02013;2 cases per 100,000 people per year. Characterized by an immune-mediated polyneuropathy, GBS often follows infections or immunological triggers, including vaccinations. The syndrome is classified into three main subtypes based on electrophysiological findings: acute inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN), and acute motor sensory axonal neuropathy (AMSAN). The pathophysiology of GBS involves molecular mimicry between microbial antigens and nerve structures, particularly affecting gangliosides and myelin proteins. Diagnosis primarily relies on clinical history, with lumbar puncture and electroneuromyogram used to confirm and differentiate subtypes. Treatment includes intravenous immunoglobulins or therapeutic plasma exchange associated with symptomatic treatment, especially mechanical ventilation if needed. Prognosis is generally favorable with a low mortality rate (&#x0003c;&#x02009;5%) overall, but neurological sequelae can occur. Current research continues to explore novel therapeutic approaches, including complement-targeted therapies. Despite advancements, progress in specific treatments has been limited, and ongoing evaluation of potential biomarkers such as neurofilament light chains may enhance prognosis prediction and management strategies.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Guillain-Barr&#x000e9; syndrome</kwd><kwd>Miller-Fisher</kwd><kwd>Acute polyradiculoneuritis</kwd><kwd>Bickerstaff encephalitis</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; La Soci&#x000e9;t&#x000e9; de R&#x000e9;animation de Langue Francaise = The French Society of Intensive Care (SRLF) 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">The Guillain-Barr&#x000e9; syndrome (GBS) is the leading cause of acute flaccid tetraplegia worldwide, with an incidence of approximately 1&#x02013;2 cases per 100,000 inhabitants per year [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. The incidence is slightly higher in men than in women (sex ratio of 1.5) and increases with age, although it can occur at any age [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. GBS is an immune-mediated polyneuropathy often triggered by an infection or another immunological event, such as vaccination. Diagnosis is primarily based on anamnesis and clinical evaluation. Additional tests, including lumbar puncture and electroneuromyogram (ENMG), can often remain normal in the early stages and are generally used to rule out other differential diagnoses. Admission to the ICU is necessary in cases of respiratory failure (30% of cases, with 20% needing mechanical ventilation), impaired swallowing or dysautonomia (10% of cases) [<xref ref-type="bibr" rid="CR2">2</xref>]. Treatment options include intravenous immunoglobulins or therapeutic plasma exchange, alongside supportive care. The long-term prognosis is generally favorable, with a mortality rate of less than 5%, although neurological sequelae can occasionally occur.</p><p id="Par3">Although this syndrome may have been partially described in 1859 by Landry as &#x0201c;ascending paralysis,&#x0201d; it was definitively characterized as a distinct nosological entity in 1916 by Guillain, Barr&#x000e9;, and Strohl [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Their description included the clinical presentation, the biochemical feature of albumin-cytological dissociation, and electrophysiological findings, distinguishing GBS from other neuropathies, notably infectious neuropathies such as acute anterior poliomyelitis. GBS is classically divided into three types: acute inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN), and acute motor sensory axonal neuropathy (AMSAN) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par4">In this narrative review, we will successively discuss the triggering events of GBS, its pathophysiology, the classical clinical presentation, its diagnosis, the treatment strategies, the complications that can occur and the outcome, especially in severe forms requiring ICU.</p><sec id="Sec2"><title>Triggering events</title><p id="Par5">A few years after the initial description of GBS, physicians noticed a temporal link between symptom onset and recent infections, highlighting an abnormal immune response as a trigger [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Indeed, two-thirds of GBS cases are preceded by an acute infectious event, as indicated by medical history and serological data (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). <italic>Campylobacter jejuni</italic> is the most frequently identified infectious agent, particularly in Asia, where it accounts for about half of the cases [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>]. Other bacterial triggers include <italic>Mycoplasma pneumoniae</italic> and <italic>Haemophilus influenzae</italic> [<xref ref-type="bibr" rid="CR11">11</xref>], while viral triggers include cytomegalovirus, Epstein-Barr virus, Influenza-A virus [<xref ref-type="bibr" rid="CR12">12</xref>], Hepatitis E virus [<xref ref-type="bibr" rid="CR13">13</xref>], and arboviruses (Chikungunya, Dengue, and Zika viruses) [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Whereas some associations have been proposed on case-series, six infectious agents have been conclusively associated with GBS through well-designed case-control studies: <italic>Campylobacter jejuni</italic>, cytomegalovirus, Epstein-Barr virus, Hepatitis E virus, <italic>Mycoplasma pneumoniae</italic>, and Zika virus [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. There have also been reports of GBS following SARS-CoV-2 infection [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par6">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Pathophysiology of Guillain-Barr&#x000e9; syndrome</p><p><bold>A</bold>, schematic view of the peripheral nerve showing the axon, the myelin sheath and the saltatory conduction from one node of Ranvier to another in normal condition; <bold>B</bold>, schematic view of the node of Ranvier showing voltage-gated sodium channel and gangliosides; <bold>C</bold>, immune system recognizes gangliosides expressed on the surface of <italic>Campylobacter jejuni</italic> and induces the production of gangliosides antibodies that are able to fix gangliosides expressed on the node of Ranvier; this correspond to what is coined as molecular mimicry. Antibodies fixation will lead to complement activation and then after macrophage recruitment</p></caption><graphic xlink:href="13613_2025_1464_Fig1_HTML" id="d33e320"/></fig>
</p><p id="Par7">More rarely GBS has been reported post-vaccination, particularly after the Semple type rabies vaccine and various influenza vaccines, with an incidence of approximately 1 case per 100,000 vaccinations. The risk of GBS following influenza vaccination is lower than after an influenza infection however [<xref ref-type="bibr" rid="CR12">12</xref>]. Cases have also been reported after vaccinations against Human Papilloma virus, measles, mumps, rubella, <italic>meningococcus</italic> (tetravalent conjugate), and SARS-CoV-2 [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. However, the association with SARS-CoV-2 vaccines should be viewed in the context of a global mass vaccination campaign [<xref ref-type="bibr" rid="CR16">16</xref>]. Globally, the protection offered by vaccination against infections that may cause GBS outweighs the risk of developing GBS following vaccination.</p><p id="Par8">Other triggers include immunotherapies (anti-tumor necrosis factor, type I interferons, immune checkpoint inhibitors), chemotherapies (platin salts, brentuximab), surgery, or traumatic brain injury [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>].</p></sec><sec id="Sec3"><title>Pathophysiology</title><p id="Par9">GBS is classified into three subtypes based on electrophysiological findings: AIDP, AMAN and AMSAN. The pathophysiology of AMAN and AMSAN is the best understood, primarily attributed to molecular mimicry between infectious agent epitopes and nerve structures [<xref ref-type="bibr" rid="CR20">20</xref>]. IgG antibodies targeting gangliosides, especially GM1 and GD1a at Ranvier nodes, have been identified in these subtypes (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>]. In animal models, GBS-like symptoms can be induced by immunizing against these gangliosides, demonstrating a high homology between these nerve surface gangliosides and the glycan structures of various infectious agents [<xref ref-type="bibr" rid="CR23">23</xref>]. This molecular mimicry hypothesis is well-documented, particularly for <italic>Campylobacter jejuni</italic> [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref>]. Evidence suggests a similar mechanism for AIDP, with antibodies targeting myelin proteins and structures at the nodes of Ranvier, although the specific target antigens remain unknown [<xref ref-type="bibr" rid="CR25">25</xref>]. The complement pathway, initiated by C1q binding, plays a crucial role, with C3 fragment deposition being more pronounced in GBS patients than in healthy controls [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par10">Although a neuromuscular biopsy is not required for diagnosis, pathological data show complement deposition and macrophage infiltration in AIDP [<xref ref-type="bibr" rid="CR27">27</xref>], AMSAN, and AMAN cases, with T lymphocytes commonly found in AIDP [<xref ref-type="bibr" rid="CR26">26</xref>]. Myelin degradation in AIDP leads to conduction velocity reductions, while functional blockades characterize AMAN and AMSAN, disrupting nerve impulses due to Na+/K&#x02009;+&#x02009;ATPase blockade at Ranvier nodes [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. While molecular mimicry is a key factor in GBS pathophysiology, other factors, including genetic predispositions, remain largely underexplored [<xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR33">33</xref>]. Only a small percentage of <italic>Campylobacter jejuni</italic> infections lead to GBS, with certain strains linked to outbreaks [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. While most patients experience only one GBS episode, 2&#x02013;5% may have recurrent episodes [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Recently, antibodies targeting antigens at the node of Ranvier or the paranode have been implicated in GBS and in treatment-resistant chronic inflammatory demyelinating neuropathies (also called auto-immune nodo-paranodopathies) [<xref ref-type="bibr" rid="CR38">38</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref>]. Interestingly, some of these patients initially presented with an acute clinical pattern closely resembling GBS [<xref ref-type="bibr" rid="CR40">40</xref>]. This observation has led experts to speculate that certain cases of GBS, especially those responding poorly to treatment, may be associated with antibodies against proteins such as neurofascin or contactin [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>].</p><p id="Par11">Although most patients recover spontaneously, irreversible damage can occur due to secondary axonal degeneration, resulting from persistent blockades or prolonged axonal denudation [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>].</p></sec><sec id="Sec4"><title>Clinical presentation</title><sec id="Sec5"><title>Classical presentation</title><p id="Par12">GBS typically presents as a rapidly progressing, ascending symmetrical sensorimotor deficit [<xref ref-type="bibr" rid="CR45">45</xref>]. It evolves through three distinct phases: progression, plateau, and recovery. In its classic form, patients often first experience with sensory disturbance (paresthesia, ataxia, radicular pain) in the lower limbs, which gradually ascends to the upper limbs over days&#x02014;rarely hours&#x02014;followed closely by motor deficits [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. Initially, tendon reflexes may be present but will progressively decrease and eventually disappear (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Radicular pain and severe lumbar pain are common and can complicate the initial diagnosis, sometimes appearing as the first signs of the disease. The progression phase lasts, by the definition, less than four weeks, typically less than two weeks in 80% of cases [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. This timing enables to distinguish GBS from other forms of subacute or chronic neuropathies for which an extensive work-up is mandatory [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. At the peak of the disease, motor symptoms can lead to tetraplegia, as well as paralysis of the facial, pharyngeal, and laryngeal muscles, resulting in impaired swallowing and aspiration. Involvement of the respiratory muscles can lead to respiratory failure, necessitating mechanical ventilation [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. Dysautonomia, characterized by blood pressure and pulse lability, is also common. Patients may experience cardiac arrhythmias, blood pressure instability, urinary retention, or functional ileus [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. Dysautonomia is more frequent in severe cases, but it can occasionally present as a primary feature with minimal sensorimotor impairment.</p><p id="Par13">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Guillain-Barr&#x000e9; syndrome diagnostic criteria according to Brighton&#x02019;s collaboration group. According Shahrizaila et al. Lancet 2021</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="4">Brighton Collaboration (level of diagnostic certainty)</th></tr><tr><th align="left">Level 1 (highest)</th><th align="left">Level 2</th><th align="left">Level 3</th><th align="left">Level 4 (lowest)</th></tr></thead><tbody><tr><td align="left">
<bold>Clinical features</bold>
</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Bilateral and flaccid weakness of limbs</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left"/></tr><tr><td align="left">Decreased or absent deep tendon reflexes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left"/></tr><tr><td align="left">Absence of alternative diagnosis</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td></tr><tr><td align="left">
<bold>Additional clinical features</bold>
</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Monophasic course, time between onset and plateau 12&#x000a0;h to 28 days</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left"/></tr><tr><td align="left">Relative symmetry</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Mild sensory symptoms or signs</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Progress (usually after 2&#x02013;4 weeks of plateau)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Cranial nerve involvement (facial, bulbar and oculomotor)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Autonomic dysfunction</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Absence of fever at the onset of neuritic symptoms</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">
<bold>CSF analysis</bold>
</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">CSF white cells count&#x02009;&#x0003c;&#x02009;50/microL (usually&#x02009;&#x0003c;&#x02009;10)</td><td align="left">Yes</td><td align="left">Yes*</td><td align="left"/><td align="left"/></tr><tr><td align="left">CSF protein raised (after week 1)</td><td align="left">Yes</td><td align="left">Yes*</td><td align="left"/><td align="left"/></tr><tr><td align="left">
<bold>Nerve conduction studies</bold>
</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Consistent with conduction slowing and block</td><td align="left">Yes</td><td align="left">Yes*</td><td align="left"/><td align="left"/></tr></tbody></table><table-wrap-foot><p>Abbreviations: CSF, cerebrospinal fluid, * needed to have definite GBS</p></table-wrap-foot></table-wrap>
</p><p id="Par14">Overall, 20% of patients require mechanical ventilation, and 10&#x02013;20% experience significant dysautonomia during the acute phase. Some patients endure severe pain that is difficult to manage despite multiple analgesic treatments [<xref ref-type="bibr" rid="CR50">50</xref>], while others may primarily experience ataxia.</p><p id="Par15">The plateau phase follows, during which symptoms stabilize and can last from a few days to several weeks, or even months in the most severe cases, such as those in ICU with a severe tetraplegia or a locked-in syndrome [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. The recovery phase follows, which can extend over several months.</p></sec><sec id="Sec6"><title>Atypical presentation</title><p id="Par16">Atypical presentations of GBS have been described, as reviewed by Yuki and Wakerley [<xref ref-type="bibr" rid="CR53">53</xref>&#x02013;<xref ref-type="bibr" rid="CR58">58</xref>] (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). The most common variant is Miller-Fisher syndrome, characterized by ophthalmoplegia, ataxia, and areflexia [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. This variant is considered a specific form of AMAN and is often associated with positive anti-GQ1b antiganglioside antibodies. Miller-Fisher syndrome can progress to a more typical GBS presentation, with symptoms descending from the initial signs to tetraplegia. Bickerstaff&#x02019;s brainstem encephalitis, which combines GBS-like symptoms with altered consciousness, is a very rare entity [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. It may result from the direct action of anti-GQ1b antibodies on the ascending reticular activating system in the brainstem. When a GBS patient exhibits altered consciousness, more common complications, such as hyponatremia or posterior reversible encephalopathy syndrome secondary to extreme blood pressure fluctuation in the context of dysautonomia should be considered (see below) [<xref ref-type="bibr" rid="CR49">49</xref>].</p><p id="Par17">
<fig id="Fig2"><label>Fig. 2</label><caption><p>Different forms of Guillain-Barr&#x000e9; syndrome</p><p>Black areas represent localization of the neurological symptoms. The blurred representation stands for ataxia. The bed represents altered consciousness</p></caption><graphic xlink:href="13613_2025_1464_Fig2_HTML" id="d33e741"/></fig>
</p></sec></sec><sec id="Sec7"><title>Diagnosis</title><p id="Par18">The diagnosis of GBS is primarily clinical, with lumbar puncture and ENMG used to confirm the diagnosis and exclude differential diagnoses (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The first set of diagnostic criteria was proposed by the National Institute of Neurological Disorders and Stroke (NINDS) in 1978 [<xref ref-type="bibr" rid="CR62">62</xref>]. In 2011, an international committee of experts convened in Brighton to update these criteria, aiming to standardize epidemiological and pharmacovigilance studies (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR63">63</xref>]. Notably, neither the NINDS nor the Brighton criteria require additional diagnostic tests for a diagnosis of &#x0201c;probable GBS&#x0201d;. However, the Brighton criteria include lumbar puncture and ENMG results for confirming a diagnosis of &#x0201c;definite GBS&#x0201d;.</p><p id="Par19">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Differential diagnosis of Guillain-Barr&#x000e9; syndrome and its atypical forms</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Guillain-Barr&#x000e9; syndrome</th></tr></thead><tbody><tr><td align="left">
<bold><italic>Transverse myelitis</italic></bold>
</td></tr><tr><td align="left">
<italic>&#x02003;Mycoplasma pneumoniae</italic>
</td></tr><tr><td align="left"><italic>&#x02003;Herpes simplex virus &#x02212;&#x02009;1 and &#x02212;&#x02009;2</italic>,<italic> cytomegalovirus</italic>,<italic> Epstein-Barr virus</italic>,<italic> varicella zoster virus</italic></td></tr><tr><td align="left">&#x02003;Post-infectious myelitis</td></tr><tr><td align="left">&#x02003;Initial manifestation of demyelinating disease (multiple sclerosis, neuromyelitis optica, etc.)</td></tr><tr><td align="left">&#x02003;Nitrogen protoxide (therapeutic and recreational use)</td></tr><tr><td align="left">
<bold><italic>Spinal cord lesion</italic></bold>
</td></tr><tr><td align="left">&#x02003;Spinal compression (discal protrusion, epidural abscess or hematoma)</td></tr><tr><td align="left">&#x02003;Anterior spinal cord artery occlusion</td></tr><tr><td align="left"><bold><italic>Acute</italic></bold>,<bold><italic> subacute and chronic neuropathies</italic></bold></td></tr><tr><td align="left">&#x02003;Infections (Diphteria, West-Nile virus, HIV, tick paralysis, Lyme disease, etc.)</td></tr><tr><td align="left">&#x02003;Toxins or fish consumption (tetrodotoxine, lead, thallium, arsenic, etc.)</td></tr><tr><td align="left">&#x02003;Drugs (cisplatine, brentuximab, etc.) *</td></tr><tr><td align="left">&#x02003;Carential neuropathies (B1, B9, B12 vitamins)</td></tr><tr><td align="left">&#x02003;Diabetes mellitus neuropathy</td></tr><tr><td align="left">&#x02003;Hematological malignancies (MGUS, POEMS syndrome, CANOMAD, etc.)</td></tr><tr><td align="left">&#x02003;Sarco&#x000ef;dosis</td></tr><tr><td align="left">&#x02003;Porphyria</td></tr><tr><td align="left">&#x02003;Acute onset CIDP and auto-immune nodopathies (anti-neurofascein 155, anti-contactin-1 and probably anti-Caspr1 and anti-pan-neurofascein) <sup>$</sup></td></tr><tr><td align="left">
<bold><italic>Anterior horn cells disease / lower motor neuron syndrome</italic></bold>
</td></tr><tr><td align="left">&#x02003;Poliomyelitis, non-poliomyelitis enteroviruses (<italic>enterovirus</italic> 71), West-Nile virus</td></tr><tr><td align="left"><italic>&#x02003;Herpes simplex virus &#x02212;&#x02009;1 and &#x02212;&#x02009;2</italic>,<italic> cytomegalovirus</italic>,<italic> Epstein-Barr virus</italic>,<italic> varicella zoster virus *</italic></td></tr><tr><td align="left">&#x02003;Rabies, HIV</td></tr><tr><td align="left">
<bold><italic>Neuromuscular junction disease</italic></bold>
</td></tr><tr><td align="left">&#x02003;Myasthenia gravis</td></tr><tr><td align="left">&#x02003;Lambert-Eaton syndrome</td></tr><tr><td align="left">&#x02003;Botulism (and adverse effect of therapeutic use of toxin botulinium)</td></tr><tr><td align="left">
<bold><italic>ICU acquired weakness (neuropathy)</italic></bold>
</td></tr><tr><td align="left">
<bold><italic>Muscles diseases</italic></bold>
</td></tr><tr><td align="left">&#x02003;Acute myositis</td></tr><tr><td align="left">&#x02003;Periodic paralysis and electrolytical disturbances (hypokaliemia, hypophosphatemia, hypermagnesemia, etc.)</td></tr><tr><td align="left">&#x02003;Polymyositis and dermatomyositis</td></tr><tr><td align="left">
<bold><italic>Mitochondrial diseases</italic></bold>
</td></tr><tr><td align="left">
<bold><italic>Somatoform diseases</italic></bold>
</td></tr><tr><td align="left">
<bold>Miller-Fisher syndrome and Bickerstaff encephalitis</bold>
</td></tr><tr><td align="left">&#x02003;Myasthenia gravis</td></tr><tr><td align="left">&#x02003;Brainstem stroke</td></tr><tr><td align="left">&#x02003;Diphteria neuropathy</td></tr><tr><td align="left">&#x02003;Botulism (and adverse effect of therapeutic use of toxin botulinium)</td></tr><tr><td align="left">&#x02003;Rhombencephalitis</td></tr><tr><td align="left">&#x02003;&#x02003;Infectious (listeria spp, tuberculosis, brucellosis, Lyme disease, <italic>virus herpes simplex &#x02212;&#x02009;1 et -2</italic>,<italic> Epstein-Barr virus</italic>, JC virus, toxoplasma spp, cryptococcosis, SARS-CoV2)</td></tr><tr><td align="left">&#x02003;&#x02003;Inflammatory (multiple sclerosis, neuromyelitis optica, sarco&#x000ef;dosis, Beh&#x000e7;et disease, neurolupus, etc.)</td></tr><tr><td align="left">&#x02003;&#x02003;Tumors (lymphoma, etc.) and paraneoplastic syndromes</td></tr><tr><td align="left">&#x02003;Meningitis (inflammatory, infectious, carcinomatous and lymphoma)</td></tr><tr><td align="left">&#x02003;Gayet-Wernicke encephalopathy</td></tr></tbody></table><table-wrap-foot><p>* could also represent triggers of GBS. <sup>$</sup> these nosological entities have been described very recently and their detailed clinical spectrum is not entirely known</p><p>Abbreviations: CANOMAD, chronic ataxic neuropathy, ophthalmoplegia, M-protein, cold agglutinins, and disialosyl antibodies (GD1b and GQ1b among others); Caspr1, contactin-associated protein 1; CIDP, chronic inflammatory demyelinating neuropathy; JC virus, John Cunningham virus; HIV, Human immunodeficiency virus; MGUS, monoclonal gammopathy of undetermined significance; POEMS, polyradiculoneuropathy, organomegalia, endocrinopathies, M component and skin; SARS-CoV2, severe acute respiratory syndrome coronavirus 2</p></table-wrap-foot></table-wrap>
</p><sec id="Sec8"><title>Lumbar puncture</title><p id="Par20">The primary purpose of a lumbar puncture in GBS evaluation is to exclude other potential diagnoses (e.g. Lyme disease, or varicella-zoster virus infection and other infections mainly). In the absence of conditions like diabetes mellitus or spinal compression, the presence of albumin-cytological dissociation&#x02014;characterized by elevated protein levels with fewer than 10 cells per &#x000b5;L&#x02014;is highly indicative of an inflammatory polyradiculitis [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. However, albumin-cytological dissociation may be absent in up to 50% of cases during the first week of symptom onset and in 10&#x02013;30% of cases during the second week. While a mild cellular response can occasionally occur, cell counts rarely exceed 50 cells per &#x000b5;L. A pleocytosis between 10 and 50 cells per &#x000b5;L should prompt further investigation, as it may suggest an alternative diagnosis (e.g. infectious polyradiculonevritis mainly) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>) [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. A lumbar puncture is particularly crucial when bilateral facial palsy or a cutaneous vesicular eruption is present, as these symptoms may indicate Lyme disease or varicella-zoster virus infection. If the CSF analysis is normal, it is not necessary to repeat it if the diagnosis is otherwise confirmed.</p></sec><sec id="Sec9"><title>Electroneuromyogram</title><p id="Par21">Like lumbar puncture, ENMG can initially yield normal results if performed early after symptom onset (in the first week). However, when abnormal, ENMG can confirm the diagnosis of GBS and help distinguish between its subtypes: AIDP, AMAN, and AMSAN [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]. Nerve conduction abnormalities are most pronounced around two weeks after symptom onset. Thus, if an ENMG has been performed in the first week and is normal a second one should be performed about one week later.</p><p id="Par22">Typically, ENMG should be conducted on all four limbs, examining at least four different motor nerves and three sensory nerves, along with H reflexes and F waves. In AIDP, ENMG findings may include increased distal motor latencies, decreased conduction velocities, prolonged F wave latencies, temporal dispersion, and conduction block [<xref ref-type="bibr" rid="CR29">29</xref>]. In AMAN, reduced amplitudes of motor waves are observed, while AMSAN presents with decreased amplitudes in both motor and sensory waves. Some cases of AMAN and AMSAN may also exhibit conduction block [<xref ref-type="bibr" rid="CR28">28</xref>]. The ENMG is important to perform for diagnostic purposes and to rule out differential diagnoses. However, its performance should not delay the initiation of immunomodulatory treatment in case of clinical suspicion. It is often beneficial to perform ENMG twice to accurately differentiate between these subtypes, as initial testing can sometimes be inconclusive or fail to correctly classify the subtype [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]. EMG may also be useful for prognostic purposes [<xref ref-type="bibr" rid="CR119">119</xref>]. Nevertheless, in ICU, ENMG can be compromised by artefacts that can preclude a correct analysis.</p></sec><sec id="Sec10"><title>Other exams</title><p id="Par23">Apart from EMG and lumbar puncture, the most important examination is probably a spinal cord MRI in cases of suspected spinal cord lesions. The measurement of anti-ganglioside antibodies has limited diagnostic value for several reasons: the variability in analysis kits and their sensitivity, the delay of several weeks before results are available, and the low positivity rate observed in Europe [<xref ref-type="bibr" rid="CR42">42</xref>]. However, in specific forms like Miller-Fisher syndrome, their presence is a significant diagnostic clue. Similarly, while infectious disease serologies can provide insights into the epidemiology of GBS, they are not crucial for diagnosis. Other microbiological techniques, such as cultures or PCR, are less useful given the post-infectious nature of the disease.</p><p id="Par24">A minimal etiological work-up, as recommended for neuropathy, could include the following: a complete blood count, electrolytes with creatinine, HbA1c, B12 and folate levels, HIV serology, and serum protein electrophoresis and immunofixation. In cases of atypical presentation or nitrous oxide consumption, measuring homocysteine and methylmalonic acid levels can be useful [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR68">68</xref>].</p><p id="Par25">In certain situations, particularly with asymmetrical presentation or very acute onset (&#x0003c;&#x02009;12&#x000a0;h), a cerebral or spinal MRI may be necessary to rule out a stroke. Recently, studies have suggested that nerve sonography could help in the diagnosis, as GBS patients often show enlarged nerve roots and trunks compared to controls [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. Although still preliminary, this technique could be particularly useful in the ICU. Additionally, elevated levels of neurofilament light chains have been observed in GBS patients, with their increase potentially correlating with disease severity and prognosis [<xref ref-type="bibr" rid="CR71">71</xref>&#x02013;<xref ref-type="bibr" rid="CR73">73</xref>].</p></sec><sec id="Sec11"><title>Differential diagnosis</title><p id="Par26">The main differential diagnoses of GBS include infectious and inflammatory myelitis and infectious myeloradiculitis (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The presence of a sensory level and early bladder sphincter dissynergia even in the absence of a pyramidal syndrome should raise suspicion of a spinal cord lesion. Infectious myeloradiculitis caused by varicella-zoster virus or Lyme disease can present with similar symptoms. Vesicular lesions in specific dermatomes for varicella-zoster virus or facial diplegia in Lyme disease are highly suggestive. A lumbar puncture can help establish the correct diagnosis. Acute inflammatory neuropathy can also occur in the context of HIV seroconversion, but these cases are typically subacute, developing over more than four weeks and often associated with meningitis on lumbar puncture.</p><p id="Par27">Some inflammatory neuropathies linked to systemic diseases, malignant hemopathies, or sarcoidosis can present acutely. An etiological work-up and thorough anamnesis are crucial for accurate diagnosis. A history of psychiatric symptoms, depression, or abdominal pain, especially if accompanied by dark urine, may suggest porphyria in cases of neuropathy with axonal impairment. Brainstem stroke is generally not a true differential diagnosis, as the mode of onset&#x02014;sudden versus progressive&#x02014;and brain MRI findings can easily differentiate it.</p><p id="Par28">Occasionally, certain forms of diabetic neuropathies or alcoholic neuropathies can present acutely and mimic GBS. Additional differential diagnoses are listed in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>.</p><p id="Par29">About 5% of patients initially diagnosed with GBS are finally diagnosed as having acute-onset chronic inflammatory demyelinating polyradiculoneuropathy [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR47">47</xref>] (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). This distinction is important since the treatment strategy slightly differs (repeated IV-Ig administration or use of corticosteroids). A very few patients diagnosed initially as GBS and responding poorly to treatment IV-Ig or TPE may have auto-immune para-nodopathy that constitute a recently described disease where antibodies directed against nodal or paranodal antigens (neurofascein 155, Caspr-1 or contactin) have been detected [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. Those antibodies might be look for in case of poor treatment response (see treatment section).</p><p id="Par30">
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Suspicious features for an acute onset chronic demyelinating inflammatory polyneuropathy rather than a GBS</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Major features</th><th align="left">Minor features</th></tr></thead><tbody><tr><td align="left">Progression&#x02009;&#x0003e;&#x02009;8 weeks</td><td align="left">No facial or bulbar weakness</td></tr><tr><td align="left">More than 3 treatment related fluctuations</td><td align="left">No respiratory weakness</td></tr><tr><td align="left">Slower progression (possibly&#x02009;&#x0003e;&#x02009;2 weeks from onset to nadir)</td><td align="left">No preceding infection</td></tr><tr><td align="left"/><td align="left">Absence of IgG anti-ganglioside antibodies</td></tr><tr><td align="left"/><td align="left">Marked sensory abnormalities (including ataxia)</td></tr><tr><td align="left"/><td align="left">Ultrasound evidence of widespread peripheral nerve enlargement</td></tr><tr><td align="left"/><td align="left"><p>Early significant reduction in motor nerve conduction</p><p>velocity</p></td></tr><tr><td align="left" colspan="2">Antibodies against nodal&#x02013;paranodal antigens should be tested (important for treatment options)</td></tr></tbody></table></table-wrap>
</p></sec></sec><sec id="Sec12"><title>Complications</title><sec id="Sec13"><title>Dysautonomia</title><p id="Par31">Depending on the criteria used for diagnosis, between 10% and 50% of GBS patients experience dysautonomia due to autonomic nervous system involvement [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR75">75</xref>]. However, it is crucial to rule out other causes of hypotension or cardiac arrhythmias, such as sepsis secondary to nosocomial infection, bleeding, or pulmonary embolism, before diagnosing dysautonomia.</p><p id="Par32">Symptoms of dysautonomia include blood pressure fluctuations, cardiac arrhythmias, ileus, and urinary retention. The most common symptoms are sinus tachycardia, elevated blood pressure, and blood pressure instability [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR74">74</xref>]. Unfortunately, there is no consensus definition of dysautonomia in GBS, and no specific recommendations on how and when to assess it. Some authors suggest diagnosing dysautonomia if systolic blood pressure varies by more than 85 mmHg within the same day without any confounding cause. This threshold is considered more sensitive than the previously proposed 40 or 50 mmHg daily variation [<xref ref-type="bibr" rid="CR74">74</xref>]. Patients with blood pressure instability and tachycardia may be at a higher risk of cardiac arrhythmias, especially asystole. Although some data suggest that dysautonomia can occur in mild forms of GBS, the risk appears more prominent in severe cases presenting with tetraplegia, respiratory impairment, and swallowing difficulties during the ascending or plateau phase [<xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR75">75</xref>].</p><p id="Par33">23% of GBS patients have a heart rate above 100 beats per minute, rising to 75% among those requiring mechanical ventilation [<xref ref-type="bibr" rid="CR75">75</xref>]. Even minimal stimulation can trigger severe bradycardia in these patients. In the most severe cases, mild activities such as tracheal suctioning, intubation, mouth care, or bathing can provoke severe dysautonomia symptoms, particularly bradycardia. Some teams recommend having 1&#x000a0;mg of IV atropine readily available for severe dysautonomia. Outside of severe bradycardia, conservative management is generally preferred. It is risky to use antihypertensive drugs or antiarrhythmics unless absolutely necessary. A pacemaker is rarely indicated. Ileus is frequently problematic and can lead to functional bowel obstruction. Maintaining normal potassium levels and avoiding sedatives is advisable. Posterior reversible encephalopathy syndrome due to extreme blood pressure fluctuation is possible (7% of dysautonomic patients), and may be exacerbated by IV immunoglobulin treatment [<xref ref-type="bibr" rid="CR49">49</xref>]. Takotsubo cardiomyopathy is another rare life-threatening complication of GBS, probably enhanced by dysautonomia, secondary to the activation of the sympathetic nervous system and an increase in catecholamines [<xref ref-type="bibr" rid="CR120">120</xref>].</p></sec><sec id="Sec14"><title>Salt wasting syndrome or inappropriate secretion of antidiuretic hormone</title><p id="Par34">The exact nature of hyponatremia in GBS remains debated. Some experts suggest that hyponatremia is primarily due to salt-wasting syndrome [<xref ref-type="bibr" rid="CR76">76</xref>&#x02013;<xref ref-type="bibr" rid="CR78">78</xref>]. A recent pathophysiological study proposed that this could be linked to altered adrenal gland autoregulation due to autonomic nervous system dysfunction, although further confirmation is needed [<xref ref-type="bibr" rid="CR78">78</xref>]. IV immunoglobulin can also contribute to hyponatremia by increasing serum protein levels, leading to pseudohyponatremia. Clinically, hyponatremia typically responds to the administration of sodium chloride, either intravenously or orally, with the dosage adjusted based on urinary sodium losses. It is important to note that hyponatremia can exacerbate neurological symptoms.</p></sec><sec id="Sec15"><title>Vivid Dreams</title><p id="Par35">GBS patients can occasionally experience altered sleep with depersonalization symptoms, described as vivid dreams, which may be misdiagnosed as delirium [<xref ref-type="bibr" rid="CR79">79</xref>]. These symptoms may be underdiagnosed, especially in severe patients on MV, where communication is impaired. In cases where such complaints arise in patients not yet on MV, consideration should be given to transferring them to the ICU, as these symptoms could be associated with dysautonomia and a more severe illness.</p></sec></sec><sec id="Sec16"><title>Treatment strategies in Guillain-Barr&#x000e9; syndrome</title><sec id="Sec17"><title>Specific treatments</title><p id="Par36">Treatment strategies for GBS have been extensively documented and summarized in Cochrane reviews [<xref ref-type="bibr" rid="CR80">80</xref>&#x02013;<xref ref-type="bibr" rid="CR82">82</xref>]. The European Academy of Neurology recently published guidelines [<xref ref-type="bibr" rid="CR42">42</xref>]. The standard of care involves the administration of immunotherapy, either therapeutic plasma exchange (TPE) or intravenous immunoglobulins (IV-Ig) for patients still in the ascending phase, ideally in the first 2 weeks of symptom&#x02019;s onset (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>) [<xref ref-type="bibr" rid="CR42">42</xref>]. TPE was the first validated as a treatment for GBS in the 1980s, with several randomized controlled trials (RCTs) demonstrating that it improved the proportion of patients able to walk without aid at one month compared to placebo [<xref ref-type="bibr" rid="CR80">80</xref>]. Whereas it has been shown that 6 TPE was not better than 4 even in severe patients that were mechanically ventilated, it has been shown that 2 TPE was better than placebo in patients with mild GBS [<xref ref-type="bibr" rid="CR83">83</xref>]. Studies showed also that using fresh frozen plasma as replacement fluid was not superior to using albumin and crystalo&#x000ef;ds but was associated to more side-effects [<xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR84">84</xref>]. It should be noted that risk of bleeding, infection and severe cardiovascular instability are a classical counter-indication for TPE or should be at least discussed. Recent European Academy of Neurology guidelines recommend, if TPE is chosen, to perform 4 to 5 TPE over one to 2 weeks for a total exchanged volume of 12 to 15&#x000a0;L [<xref ref-type="bibr" rid="CR42">42</xref>].</p><p id="Par37">
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Treatment strategies in Guillain-Barr&#x000e9; syndrome</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="3">Specific GBS treatments</th></tr><tr><th align="left">Treatment</th><th align="left">Modalities</th><th align="left">Dosage</th></tr></thead><tbody><tr><td align="left">Therapeutic plasma exchange</td><td align="left"><p>4 to 5 sessions in the severe ICU forms</p><p>Replacement solute: Albumin 5% (or fresh frozen plasma if altered blood coagulation, e.g. fibrinogen&#x02009;&#x0003c;&#x02009;2&#x000a0;g/L)</p></td><td align="left">One course of 12 to 15&#x000a0;L in 4 to 5 exchanges over 1&#x02013;2 weeks</td></tr><tr><td align="left">IV-immunoglobulins</td><td align="left">Administration over 5 days (more rapid administration could be associated with more TRFs)</td><td align="left">Total dosage of 2&#x000a0;g/kg (0.4&#x000a0;g/kg for 5 days) IV</td></tr><tr><td align="left">Second course</td><td align="left">Only in case of TRFs</td><td align="left">Total dosage of 2&#x000a0;g/kg (0.4&#x000a0;g/kg for 5 days) IV</td></tr><tr><td align="left">Switch of TPE to IV-Ig or IV-Ig to TPE</td><td align="left"><p>Not recommended (even if no clear improvement or deterioration occurs)</p><p>In auto-immune nodopathies, TPE might be effective whereas IV-Ig are not</p></td><td align="left">-</td></tr><tr><td align="left">Corticostero&#x000ef;ds</td><td align="left">Not recommended</td><td align="left">-</td></tr><tr><td align="left" colspan="3">
<bold>Symptomatic treatments</bold>
</td></tr><tr><td align="left" colspan="3"><bold>Mechanical ventilation</bold>: (see Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>)</td></tr><tr><td align="left" colspan="3"><p><bold>Pain management</bold>:</p><p>&#x02003;- Antiseizure medications used for neuropathic pain, particularly gabapentin and pregabalin or tricyclic antidepressants. Carbamazepin that has been tested is not preferred due to possible drug interaction. Paracetamol can be problematic due to possible mild liver enzyme elevation in the initial phase. The use of local anesthetics, especially lidocaine 5% plaster might be discussed.</p></td></tr><tr><td align="left" colspan="3"><p><bold>Prevention of further complications</bold>:</p><p>&#x02003;- Thromboembolic events prevention</p><p>&#x02003;- Early mobilization and appropriate positioning to prevent contractures, to avoid <italic>equinus varus</italic> and the development of osteoma</p><p>&#x02003;- Bowel dysfunction close surveillance</p><p>&#x02003;- Glucose level monitoring</p></td></tr></tbody></table><table-wrap-foot><p>Abbreviations: Ht, hematocrit; IV, intravenous; IV-Ig, IV immunoglobulins; TPE, therapeutic plasma exchange; TRFs, treatment related fluctuations</p></table-wrap-foot></table-wrap>
</p><p id="Par38">In the 1990s, RCTs compared IV-Ig with TPE found no significant difference in the primary outcome of patients being able to walk without aid at one month [<xref ref-type="bibr" rid="CR81">81</xref>]. The recommended dosage for patients unable to stand-up is 0.4&#x000a0;g per kg per day for 5 days [<xref ref-type="bibr" rid="CR42">42</xref>]. A more rapid administration (2 days versus 5 days) could be associated to more treatment related fluctuations and should thus be discouraged [<xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR85">85</xref>]. Recently, the Erasmus group in the Netherlands conducted a randomized, double-blinded, placebo-controlled trial to test the efficacy of a second course of IV-Ig, 2&#x000a0;g/kg administered over 5 days, administered 7 to 9 days after the initial course, in patients with a poor prognosis, assessed by a modified Erasmus Guillain-Barr&#x000e9; syndrome Outcome Score&#x02009;&#x02265;&#x02009;6 [<xref ref-type="bibr" rid="CR86">86</xref>]. This trial, which included 93 patients, did not show any significant difference in the primary outcome, the Guillain-Barr&#x000e9; syndrome disability score at 4 weeks post-inclusion, nor any outcome measure but the second course was associated with more frequent thromboembolic complications.</p><p id="Par39">In current clinical practice, most GBS patients are treated with a single course of IV-Ig, as it can be administered by non-specialized teams and does not require the specific equipment needed for TPE. Nevertheless, TPE could be efficient in auto-immune para-nodopathies resistant to IV-Ig [<xref ref-type="bibr" rid="CR87">87</xref>]. Some limited data suggest that IV-Ig could be associated with a lower duration of mechanical ventilation [<xref ref-type="bibr" rid="CR88">88</xref>]. The environmental impact has, until now, nevertheless not be evaluated.</p><p id="Par40">One recurrent discussion in ICU is whether a mechanically ventilated patients should be treated by a second course of IV-Ig or a switch from IV-Ig to TPE or from TPE to IV-Ig for insufficient or no response at one month. This question is insufficiently addressed today in the literature but the guidelines recommend against an alternative treatment (TPE or IV-Ig) as they do not recommend to administer IV-Ig immediately after TPE [<xref ref-type="bibr" rid="CR42">42</xref>]. One RCT comparing TPE, IV-Ig and IV-Ig started after the last TPE did not found any difference in outcome [<xref ref-type="bibr" rid="CR89">89</xref>] and as the efficacy of IV-Ig and TPE seems similar, the experts consider that the effect of TPE after IV-Ig has no reason to differ.</p><p id="Par41">This former question is slightly different from the case of a patient that initially improved or stabilized with treatment, and who secondarily deteriorates with a neurological worsening. This condition is called treatment related fluctuations and might be present in 10% of GBS patients according to one study [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR90">90</xref>]. These fluctuations might beneficiate from a re-treatment with either IV-Ig or TPE according to observational studies, i.e. no RCT available [<xref ref-type="bibr" rid="CR42">42</xref>].</p><p id="Par42">In patients with poor response to treatment, continuous worsening, or relapse after treatment, testing for antibodies against nodal&#x02013;paranodal antigens might be valuable [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR42">42</xref>].</p><p id="Par43">It should be noted that several well-designed studies have assessed the effectiveness of corticosteroids, administered either orally or intravenously. These studies, summarized by the Cochrane group, consistently found no beneficial effect [<xref ref-type="bibr" rid="CR82">82</xref>]. Some prospective studies even suggested a potential harm with a worsening of symptoms when corticosteroids were used in this context. Consequently, corticosteroids are not recommended for the treatment of GBS [<xref ref-type="bibr" rid="CR42">42</xref>].</p></sec><sec id="Sec18"><title>Symptomatic treatments</title><p id="Par44">In addition to specific treatments, it is crucial to manage respiratory failure, alleviate pain, dysautonomia and prevent decubitus complications in GBS patients.</p><p id="Par45">
<list list-type="simple"><list-item><label>i.</label><p id="Par46"><italic>Mechanical Ventilation</italic>.</p></list-item></list>
</p><p id="Par47">
<list list-type="alpha-lower"><list-item><p id="Par48">Need for mechanical ventilation.</p></list-item></list>
</p><p id="Par49">Various studies have suggested that delayed use of mechanical ventilation (MV) in GBS was associated with increased morbidity, including aspiration pneumonia and cardio-respiratory arrest [<xref ref-type="bibr" rid="CR91">91</xref>&#x02013;<xref ref-type="bibr" rid="CR93">93</xref>]. However, a recent monocentric randomized trial including 55 patients did not found any difference in the incidence of pneumonia between patients with early VM and those with delayed VM [<xref ref-type="bibr" rid="CR94">94</xref>].</p><p id="Par50">Although the criteria for initiating MV have long been based on expert opinion and small retrospective studies, a few larger-scale studies have established robust criteria. A large French retrospective study identified six independent predictive risk factors for the need for MV: inability to cough (OR 9.09), inability to abduct shoulder to horizontal (OR 2.99), neck flexion weakness (OR 4.34), GBS disability grade&#x02009;&#x02265;&#x02009;4 (wheelchair bound or bedridden) (OR 2.53), a delay of less than 7 days between symptom onset and hospital admission (OR 2.51), and liver cytolysis (OR 2.09) (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>) [<xref ref-type="bibr" rid="CR95">95</xref>]. The presence of four of these criteria was associated with an 85% risk of requiring MV. Additionally, the presence of dysautonomia has also been identified as a risk factor for requiring MV. The EGRIS (Erasmus GBS Respiratory Insufficiency Score) [<xref ref-type="bibr" rid="CR96">96</xref>] and mEGRIS (modified EGRIS) scores [<xref ref-type="bibr" rid="CR97">97</xref>] (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>), validated on an international cohort, assess the risk of respiratory failure within the first week after admission based on three factors: the time between disease onset and admission, bulbar involvement, and the MRC score [<xref ref-type="bibr" rid="CR96">96</xref>&#x02013;<xref ref-type="bibr" rid="CR98">98</xref>]. Clinically, assessing the patient&#x02019;s ability to lift their head off the bed and perform forced vital capacity is a common practice (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>) [<xref ref-type="bibr" rid="CR99">99</xref>&#x02013;<xref ref-type="bibr" rid="CR101">101</xref>]. A single breath count (SBC), where the patient takes a maximal inspiration and counts without taking another breath, is sometimes used as an approximation [<xref ref-type="bibr" rid="CR102">102</xref>]. Inability to lift the head and an apneic count below 15 have been proposed as good markers for the need for mechanical ventilation (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>). If forced vital capacity is measured at the bedside, a value below 20&#x000a0;ml/kg or a 50% decline in 24&#x000a0;h is considered a strong prognostic factor and indicates an already advanced diaphragmatic dysfunction and should lead to prompt intubation [<xref ref-type="bibr" rid="CR42">42</xref>]. Pulse oximetry is rarely useful, as oxygen desaturation typically occurs late in restrictive respiratory insufficiency. Some electrophysiological data, such as the amplitude of the diaphragmatic muscle action potential, have been explored to predict the need for MV, but with rather disappointing results.</p><p id="Par51">
<table-wrap id="Tab5"><label>Table 5</label><caption><p>Predictive criteria for the need of mechanical ventilation in Guillain-Barr&#x000e9; syndrome</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="3">Erasmus Guillain-Barr&#x000e9; Syndrome Respiratory Insufficiency (EGRIS) score</th></tr></thead><tbody><tr><td align="left">
<bold>Parameters</bold>
</td><td align="left">
<bold>Categories</bold>
</td><td align="left">
<bold>Score</bold>
</td></tr><tr><td align="left" rowspan="3">Symptom&#x02019;s onset to hospital admission delay</td><td align="left">&#x0003e;&#x02009;7 days</td><td align="left">0</td></tr><tr><td align="left">4 to 7 days</td><td align="left">1</td></tr><tr><td align="left">&#x02264;&#x02009;3 days</td><td align="left">2</td></tr><tr><td align="left" rowspan="2">Facial or bulbar weakness at hospital admission</td><td align="left">No</td><td align="left">0</td></tr><tr><td align="left">Yes</td><td align="left">1</td></tr><tr><td align="left" rowspan="5">Motor deficit at hospital admission (<italic>Medical Research Council (MRC)</italic> scoring<sup><bold><italic>+</italic></bold></sup>)</td><td align="left">60&#x02009;&#x02212;&#x02009;51</td><td align="left">0</td></tr><tr><td align="left">50&#x02009;&#x02212;&#x02009;41</td><td align="left">1</td></tr><tr><td align="left">40&#x02009;&#x02212;&#x02009;31</td><td align="left">2</td></tr><tr><td align="left">30&#x02009;&#x02212;&#x02009;21</td><td align="left">3</td></tr><tr><td align="left">&#x02264;&#x02009;20</td><td align="left">4</td></tr><tr><td align="left">
<bold>Total score</bold>
</td><td align="left"/><td align="left">
<bold>0 to 7</bold>
</td></tr><tr><td align="left" colspan="3"><p><bold>Interpretation</bold>:</p><p>Probability of need for mechanical ventilation in the first week of hospitalization:</p><p>- score of 0 to 2, 4%&#x000a0;; score of 3 to 4, 24%&#x000a0;; and score of 5 to 7, 65%</p></td></tr><tr><td align="left" colspan="3"><sup>+</sup> Sum of MRC scoring of delto&#x000ef;ds, biceps, carpal radial extensors, iliopsoas, quadriceps and anterior tibial muscles.</td></tr><tr><td align="left" colspan="3">
<bold><italic>Modified Erasmus Guillain-Barr&#x000e9; Syndrome Respi</italic></bold>
<bold><italic>ratory Insufficiency (mEGRIS) score</italic></bold>
</td></tr><tr><td align="left">
<bold>Parameters</bold>
</td><td align="left">
<bold>Categories</bold>
</td><td align="left">
<bold>Score</bold>
</td></tr><tr><td align="left" rowspan="2">Bulbar weakness</td><td align="left">Yes</td><td align="left">5</td></tr><tr><td align="left">No</td><td align="left">0</td></tr><tr><td align="left" rowspan="8">Symptom&#x02019;s onset to hospital admission delay</td><td align="left">0</td><td align="left">7</td></tr><tr><td align="left">1</td><td align="left">6</td></tr><tr><td align="left">2</td><td align="left">5</td></tr><tr><td align="left">3</td><td align="left">4</td></tr><tr><td align="left">4</td><td align="left">3</td></tr><tr><td align="left">5</td><td align="left">2</td></tr><tr><td align="left">6</td><td align="left">1</td></tr><tr><td align="left">&#x02265; 7</td><td align="left">0</td></tr><tr><td align="left" rowspan="6">MRC score of nuchal flexion (0&#x02013;5)</td><td align="left">0</td><td align="left">10</td></tr><tr><td align="left">1</td><td align="left">8</td></tr><tr><td align="left">2</td><td align="left">6</td></tr><tr><td align="left">3</td><td align="left">4</td></tr><tr><td align="left">4</td><td align="left">2</td></tr><tr><td align="left">5</td><td align="left">0</td></tr><tr><td align="left" rowspan="11">MRC score of leg flexion (0&#x02013;10)</td><td align="left">0</td><td align="left">10</td></tr><tr><td align="left">1</td><td align="left">9</td></tr><tr><td align="left">2</td><td align="left">8</td></tr><tr><td align="left">3</td><td align="left">7</td></tr><tr><td align="left">4</td><td align="left">6</td></tr><tr><td align="left">5</td><td align="left">5</td></tr><tr><td align="left">6</td><td align="left">4</td></tr><tr><td align="left">7</td><td align="left">3</td></tr><tr><td align="left">8</td><td align="left">2</td></tr><tr><td align="left">9</td><td align="left">1</td></tr><tr><td align="left">10</td><td align="left">0</td></tr><tr><td align="left">
<bold>Total score</bold>
</td><td align="left"/><td align="left">
<bold>0 to 32</bold>
</td></tr><tr><td align="left" colspan="3"><p><bold>Interpretation</bold>:</p><p>Probability of need for mechanical ventilation at day 1, day 3 and day 7 according to a S shaped curve.</p><p>Briefly, the probability to be ventilated at day 7 is:</p><p>&#x02212;&#x02009;5%&#x000a0;for a score of 8, 25% for a score of 16 and 65% for a score of 22.</p></td></tr><tr><td align="left" colspan="3">
<bold><italic>Bedside clinical evaluation (5 criteria)</italic></bold>
</td></tr><tr><td align="left" colspan="3">Neck flexion weakness</td></tr><tr><td align="left" colspan="3">Inability to abduct shoulder to horizontal</td></tr><tr><td align="left" colspan="3">Inability to cough</td></tr><tr><td align="left" colspan="3">Inability to stand-up (GBS disability grade&#x02009;&#x02265;&#x02009;4, wheelchair bound or bedridden)</td></tr><tr><td align="left" colspan="3">A delay of less than 7 days between symptom onset and hospital admission</td></tr><tr><td align="left" colspan="3">Liver cytolysis</td></tr><tr><td align="left" colspan="3"><p><bold>Interpretation</bold>:</p><p>The presence of four of these criteria was associated with an 85% risk of requiring mechanical ventilation.</p></td></tr><tr><td align="left" colspan="3">
<bold>Other predictive parameters</bold>
</td></tr><tr><td align="left" colspan="3">Forced vital capacity&#x02009;&#x0003c;&#x02009;20 mL/kg or rapid decrease (&#x0003e;&#x02009;30% of baseline)</td></tr><tr><td align="left" colspan="3">Rapid decrease in single breath count or a value&#x02009;&#x0003c;&#x02009;15</td></tr><tr><td align="left" colspan="3">Clinical markers of autonomic failure</td></tr><tr><td align="left" colspan="3">MIP&#x02009;&#x0003c;&#x02009;&#x02212;&#x02009;40 cmH2O and MEP of &#x0003c;&#x02009;+&#x02009;30 cmH2O if performed</td></tr><tr><td align="left" colspan="3">Axonal damage at ENMG</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: ENMG, electroneuromyogram; GBS, Guillain-Barr&#x000e9; syndrome; MEP, maximal expiratory pressure; MIP, maximal inspiratory pressure</p></table-wrap-foot></table-wrap>
</p><p id="Par52">
<fig id="Fig3"><label>Fig. 3</label><caption><p>Initial management of Guillain-Barr&#x000e9; syndrome</p><p>Abbreviations: CSF, cerebrospinal fluid; FVC, forced vital capacity; MRC, medical research council motor score; SBC, single breath count</p></caption><graphic xlink:href="13613_2025_1464_Fig3_HTML" id="d33e1910"/></fig>
</p><p id="Par53">
<table-wrap id="Tab6"><label>Table 6</label><caption><p>What&#x02019;s new for the intensivist</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left">
<bold>1.</bold>
</td><td align="left"><p>
<bold>Acute-onset chronic inflammatory demyelinating polyradiculoneuropathy</bold>
</p><p>About 5% of patients initially diagnosed with GBS are finally diagnosed as having acute-onset chronic inflammatory demyelinating polyradiculoneuropathy. This distinction is important since the treatment strategy slightly differs (repeated IV-Ig administration or use of corticosteroids). The time from first neurological to maximal symptoms classically exceed 4 weeks</p></td></tr><tr><td align="left">
<bold>2.</bold>
</td><td align="left"><p>
<bold>Auto-immune nodo-paranodopathies</bold>
</p><p>Recently, antibodies targeting antigens at the node of Ranvier or the paranode have been implicated in GBS and in treatment-resistant chronic inflammatory demyelinating neuropathies (also called auto-immune nodo-paranodopathies). Interestingly, some of these patients initially presented with an acute clinical pattern closely resembling GBS. This observation has led experts to speculate that certain cases of GBS, especially those responding poorly to treatment, may be associated with antibodies directed against nodal or paranodal antigens (neurofascein 155, Caspr-1 or contactin)</p></td></tr><tr><td align="left">
<bold>3.</bold>
</td><td align="left"><p>
<bold>Treatment related fluctuations</bold>
</p><p>Some GBS patients that initially improved or stabilized with treatment can secondarily present a neurological worsening. This condition is called treatment related fluctuations and might be present in 10% of GBS patients. These fluctuations might beneficiate from a re-treatment with either IV-Ig or TPE according to observational studies. This condition should be differentiated from acute-onset chronic inflammatory demyelinating polyradiculoneuropathy</p></td></tr><tr><td align="left">
<bold>4.</bold>
</td><td align="left"><p>
<bold>Nerve sonography</bold>
</p><p>Nerve sonography could help in the diagnosis, as GBS patients often show enlarged nerve roots and trunks compared to controls</p></td></tr><tr><td align="left">
<bold>5.</bold>
</td><td align="left"><p>
<bold>Neurofilament light chains</bold>
</p><p>Elevated levels of neurofilament light chains have been observed in GBS patients and their elevation could represent a prognostic marker</p></td></tr><tr><td align="left">
<bold>6.</bold>
</td><td align="left"><p>
<bold>Complement-targeted therapies</bold>
</p><p>Strategies aimed at blocking complement activation such as eculizumab, which inhibits the cleavage of C5 into C5a and C5b and thus the final activation of the complement cascade, has been tested with inconclusive results in small RCTs. Blockade of the complement cascade before the final activation of the complement cascade might be another promising strategy.</p></td></tr></tbody></table></table-wrap>
</p><p id="Par54">For intubation, presence of significant dysautonomia should favor the use of non-hypotensive induction agents.</p><p id="Par55">Non-invasive ventilation (NIV) is usually contraindicated in the presence of swallowing disorders, bilateral facial paralysis, or ineffective cough. NIV seems thus not appropriate in the GBS due to the lack of rapid improvement in respiratory function within a few hours. However, it can be used for preoxygenation.</p><p id="Par56">
<list list-type="simple"><list-item><label>b.</label><p id="Par57">Timing of tracheostomy.</p></list-item></list>
</p><p id="Par58">The duration of MV is often prolonged in GBS with median MV times estimated between 21 and 28 days [<xref ref-type="bibr" rid="CR93">93</xref>, <xref ref-type="bibr" rid="CR95">95</xref>&#x02013;<xref ref-type="bibr" rid="CR98">98</xref>]. The lack of foot flexion ability at the end of immune therapy was proposed as a good bedside predictor of prolonged duration of MV in one study [<xref ref-type="bibr" rid="CR103">103</xref>]. In a study including 212 GBS patients hospitalized in ICU from 2001 to 2011, 22 (10%) required mechanical ventilation for more than two months, with an average time to decannulation from tracheostomy of three months [<xref ref-type="bibr" rid="CR44">44</xref>]. Risk factors for prolonged ventilation include the severity of motor deficit, the severity of axonal involvement on ENMG, advanced age, and a history of lung disease [<xref ref-type="bibr" rid="CR93">93</xref>, <xref ref-type="bibr" rid="CR100">100</xref>]. In the absence of strong data, it seems reasonable to consider a tracheostomy in a patient who remains ventilator-dependent after 2 weeks and has failed multiple weaning trials, as well as in a patient who has had at least one failed extubation. The advantages of tracheostomy in these conscious patients might include greater comfort, earlier and safer mobilization to a chair, improved oral hygiene, facilitated communication, and better assessment of swallowing and bulbar function during weaning [<xref ref-type="bibr" rid="CR104">104</xref>]. The presence of a tracheostomy allows for gradual discontinuation of respiratory assistance while keeping the cannula in place until adequate secretion clearance is restored. Dysphagia due to persistent laryngeal sensory deficit could contribute to delayed decannulation [<xref ref-type="bibr" rid="CR105">105</xref>].</p><p id="Par59">
<list list-type="simple"><list-item><label>c.</label><p id="Par60">Mechanical ventilation weaning.</p></list-item></list>
</p><p id="Par61">Weaning from ventilation should be considered once general clinical improvement has begun, usually after etiological treatment (intravenous immunoglobulins or TPE) are terminated (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). Weaning modalities are primarily based on expert opinion, as studies are limited, often monocentric, retrospective, and small in size [<xref ref-type="bibr" rid="CR100">100</xref>, <xref ref-type="bibr" rid="CR101">101</xref>, <xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR107">107</xref>] or GBS patients excluded [<xref ref-type="bibr" rid="CR132">132</xref>]. It is generally accepted that pressure ventilation modes should be favored as soon as the patient can tolerate them, with a gradual decrease in inspiratory support levels. For patients with severe GBS, this may take several days or weeks. It is also important to note that these patients are at high risk for atelectasis, and some centers favor pressure ventilation during the day and volume ventilation at night.</p><p id="Par62">
<fig id="Fig4"><label>Fig. 4</label><caption><p>Proposed mechanical ventilation weaning algorithm</p><p>Abbreviations: HR, heart rate; P/F, PaO2/FiO2 ratio; PEEP, Positive end expiratory pressure; PSV, Pressure support ventilation; RR, respiratory rate; SBP, systolic blood pressure; SBT, spontaneous breathing trial; ZEEP, zero end expiratory pressure</p></caption><graphic xlink:href="13613_2025_1464_Fig4_HTML" id="d33e2091"/></fig>
</p><p id="Par63">The usual weaning criteria (hemodynamic, respiratory, and neurological) are necessary but not sufficient to predict successful extubation in neuromuscular patients. Several prerequisites are required for successful extubation and, therefore, the initiation of a weaning trial: effective cough, low secretions, absence of ongoing respiratory infection, and the ability to lift the head off the bed (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>).</p><p id="Par64">Several studies have used forced vital capacity to guide weaning. These measurements are easily performed on recent ventilator models. Some studies suggest that SBTs can be considered when forced vital capacity exceeds 15&#x000a0;ml/kg or increases by 4&#x000a0;ml/kg from pre-intubation values [<xref ref-type="bibr" rid="CR108">108</xref>]. Another study suggested starting weaning when forced vital capacity reached 7&#x000a0;ml/kg, with increasingly prolonged SBTs, and then extubation when forced vital capacity exceeded 15&#x000a0;ml/kg and the patient breathed freely for 24 consecutive hours. Some authors recommend taking pressure measurements into account and suggest performing SBTs only when maximal inspiratory pressure &#x0003e; -20 cmH2O and/or maximal expiratory pressure&#x02009;&#x0003e;&#x02009;+&#x02009;40 cmH2O [<xref ref-type="bibr" rid="CR42">42</xref>].</p><p id="Par65">Progressive increase in the duration of SBTs over days and prolonged SBTs, lasting more than 2&#x000a0;h, have been proposed to better assess respiratory muscle fatigue [<xref ref-type="bibr" rid="CR129">129</xref>&#x02013;<xref ref-type="bibr" rid="CR131">131</xref>]. However, the ideal duration of the trials is not determined, ranging from 2 to 24&#x000a0;h, with the average proposed duration being 6 to 8&#x000a0;h. SBTs are generally repeated, with progressively increasing duration.</p><p id="Par66">There is no data on the preferred type of SBT. However, prolonged cuff-inflated T-piece SBTs carry a risk of tube obstruction, favoring the use of ZEEP. Once the inspiratory muscles can ensure normal ventilation (RR, Vt, EtCO2, P/F) during a prolonged cuff-inflated SBT, secretion drainage function might be assessed with progressively longer cuff-deflated T-piece SBTs, up to 6&#x02013;8&#x000a0;h if necessary. This technique also tests bulbar dysfunction, albeit imperfectly. Extubation failure is often related to an inability to clear secretions, and a patient who cannot tolerate a deflated cuff and cannot clear their secretions is at high risk for extubation failure. Extubation failures have also been correlated with the presence of pneumonia or persistent dysautonomia.</p><p id="Par67">The use of NIV or high-flow oxygen therapy after extubation has not yet been studied in this population but could be an interesting technique to consider a few hours after extubation in patients at risk of atelectasis.</p><p id="Par68">
<list list-type="simple"><list-item><label>ii.</label><p id="Par69">
<italic>Pain management</italic>
</p></list-item></list>
</p><p id="Par70">Pain management can be challenging due to the involvement of sensory nerves, leading to significant pain, paresthesia, radiculalgia, and low back pain [<xref ref-type="bibr" rid="CR50">50</xref>]. Treatment options are limited. A Cochrane review [<xref ref-type="bibr" rid="CR109">109</xref>] summarized data from three RCTs involving 277 GBS patients. Although the results were negative, gabapentin may be slightly effective in the acute phase, and carbamazepine may help in the long-term. In common practice, antiseizure medications used for neuropathic pain, particularly gabapentin and pregabalin, are frequently used (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). Paracetamol can be problematic due to possible mild liver enzyme elevation in the initial phase of GBS. Occasionally, level 2 or 3 analgesics are necessary, though results are inconsistent and they can trigger deleterious side-effects especially ileus. Local anesthetics, such as lidocaine 5% plaster, may be tried with a low risk of adverse effects [<xref ref-type="bibr" rid="CR110">110</xref>]. To note that if dysautonomia is present some medications should be used with caution (e.g. tricyclic antidepressants such as amitriptyline).</p><p id="Par71">
<list list-type="simple"><list-item><label>iii.</label><p id="Par72">
<italic>Maintain effective communication and provide psychological support</italic>
</p></list-item></list>
</p><p id="Par73">Maintaining effective communication is crucial for patient care and management. For patients with the most severe motor impairment, this can lead to a locked-in syndrome. Advanced communication interfaces that utilize visual tracking, subtle movement detectors, or various neurophysiological signals to control a computer can serve as essential communication aids. These devices enable patients to express their needs, symptoms, and concerns even when conventional communication is impossible, maintaining a connection with healthcare providers and family members, and reducing the psychological burden of their condition. In the context of GBS management in the ICU, these communication aids can also be invaluable for early detection of complications and for tailoring symptomatic treatment to the patient&#x02019;s specific needs. It is also essential to screen for and treat psychological disorders early during hospitalization through a multidisciplinary approach [<xref ref-type="bibr" rid="CR133">133</xref>]. Anxiety is indeed associated with weakness and bulbar dysfunction and with respiratory failure in these patients [<xref ref-type="bibr" rid="CR121">121</xref>].</p><p id="Par74">
<list list-type="simple"><list-item><label>iv.</label><p id="Par75"><italic>Prevention of further complications</italic></p></list-item></list></p><p id="Par76">Preventing decubitus complications is essential. Proper patient positioning should prevent <italic>equinus varus</italic>, a deformity that can lead to a fixed position requiring tenotomy. Early mobilization and appropriate positioning by a physiotherapist are crucial to prevent contractures and the development of osteoma, although these measures are not specific to GBS. It is also important to control blood sugar levels with an appropriate insulin therapy protocol. Indeed, the occurrence of hyperglycemia is correlated with poorer outcomes upon discharge from intensive care in ventilated GBS patients [<xref ref-type="bibr" rid="CR122">122</xref>]. Although there are no very robust studies, several studies suggest that exercise programmes improve physical outcomes such as functional mobility, cardiopulmonary function, isokinetic muscle strength, and work rate and reduce fatigue in patients with GBS. Thus, multidisciplinary rehabilitation is recommended but may be challenging in ICU because of limited patient participation [<xref ref-type="bibr" rid="CR123">123</xref>, <xref ref-type="bibr" rid="CR124">124</xref>].</p><p id="Par77">
<list list-type="simple"><list-item><label>v.</label><p id="Par78">
<italic>Therapeutic perspectives</italic>
</p></list-item></list>
</p><p id="Par79">No significant progress has been made in the treatment and management of GBS since the 1990s [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR111">111</xref>]. Strategies aimed at blocking complement activation using eculizumab, which inhibits the cleavage of C5 into C5a and C5b and thus the final activation of the complement cascade, showed promise in animal studies [<xref ref-type="bibr" rid="CR112">112</xref>]. However, these strategies have been tested in only two small phase 3 studies in humans [<xref ref-type="bibr" rid="CR113">113</xref>, <xref ref-type="bibr" rid="CR114">114</xref>]. The first study included 8 patients, with 5 receiving eculizumab and 3 receiving a placebo. The second study involved 34 patients, with 23 in the eculizumab group and 11 in the placebo group. Unfortunately, both studies did not meet their primary endpoint of independent walking at one month. A recent phase 3 RCT comparing eculizumab as an add-on therapy to IV-Ig compared to placebo that included 57 patients with severe GBS (eculizumab, <italic>n</italic>&#x02009;=&#x02009;37; placebo, <italic>n</italic>&#x02009;=&#x02009;20) failed nevertheless to demonstrate any effect on primary or secondary outcomes [<xref ref-type="bibr" rid="CR125">125</xref>]. Blockade of the complement cascade before the final activation of the complement cascade might be another strategy.</p></sec></sec><sec id="Sec23"><title>Outcome</title><p id="Par80">Despite the general perception of a &#x0201c;favourable outcome&#x0201d; in GBS, 16% of severe cases admitted to the ICU remain unable to walk independently at one year, and about 30% still experience chronic pain [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR115">115</xref>]. Only 50% of patients recover independent walking at six months with the established standard of care. Two third of GBS patients suffered complication during their ICU stay. Main complications are ventilator-associated pneumonia (between 30 and 78% of patients), acute respiratory distress syndrome (26%), septic shock (22&#x02013;24%), ileus and/or bowel perforation (17%), pulmonary embolism (7%), gastrointestinal hemorrhage (7%), acute renal failure (4%) or complications of tracheostomy (4%) [<xref ref-type="bibr" rid="CR126">126</xref>&#x02013;<xref ref-type="bibr" rid="CR128">128</xref>]. The overall mortality rate for GBS remains relatively low, around 3&#x02013;5% mainly from ICU complications [<xref ref-type="bibr" rid="CR58">58</xref>]. However, in a retrospective cohort, mortality was three times higher (6% versus 2%) among patients with dysautonomia [<xref ref-type="bibr" rid="CR74">74</xref>].</p><p id="Par81">The most important factor being associated with poor outcome in the literature is the abnormal mean amplitude of compound muscle action potential on ENMG [<xref ref-type="bibr" rid="CR116">116</xref>, <xref ref-type="bibr" rid="CR117">117</xref>]. Others factors are: older age, time from onset of disease to hospitalization of 7 days or less, and need for ventilatory support. The mEGOS (modified Erasmus GBS Score) might be used to assess this prognosis. This score includes the age at onset of the disease, the presence of diarrhea preceding GBS, and the MRC score at day 7 of admission [<xref ref-type="bibr" rid="CR118">118</xref>]. Elevated plasma levels of neurofilament light chains may serve as an early surrogate marker for long-term outcomes in the future [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR72">72</xref>].</p><p id="Par82">Recent guidelines from the neurocritical care society however suggest to consider the complete clinical condition and not only a single variable during prognostication [<xref ref-type="bibr" rid="CR115">115</xref>]. For patients with prolonged ventilation, especially the elderly, an ethical discussion regarding the intensity of care may sometimes be necessary. In such cases, the patient&#x02019;s wishes should be at the center of the discussions.</p><p id="Par83">In addition to physical disabilities, these patients often suffer from psychological burdens, including frequent post-traumatic stress disorder (PTSD) even years after their ICU stay [<xref ref-type="bibr" rid="CR44">44</xref>]. GBS constitute a significant economic burden, with prolonged ICU stays (often several months), extended rehabilitation periods, and ongoing financial support for specialized care and unemployment compensation.</p><p id="Par84">There is a critical unmet medical need for improved management of the most severe GBS patients.</p></sec></sec><sec id="Sec24"><title>Conclusion</title><p id="Par85">GBS remains a significant clinical challenge due to its varied presentation, complex pathophysiology, and potential for severe complications. Although the prognosis is generally favorable with appropriate management, the potential for long-term neurological sequelae underscores the importance of early diagnosis and treatment. While immunotherapies like IV-Ig and TPE are the mainstays of treatment, recent advancements in understanding the disease&#x02019;s molecular mechanisms offer hope for novel therapeutic approaches. However, current options for managing GBS complications, such as respiratory failure and dysautonomia, require meticulous care and tailored interventions. As research continues to unravel the intricacies of GBS, new insights into its etiology and pathophysiology may pave the way for improved patient outcomes and innovative therapies.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We would like to thank the ICU nurses, our physiotherapists, the neurophysiology department and all the fellows.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>NW wrote the initial version of the manuscript. CM and LLG critically reviewed the initial version. SD and BR reviewed the final version of the manuscript and make additional changes.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Not applicable, review article.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Not applicable, review article.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par86">Not applicable, review article.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par87">Not applicable, review article. All authors consent to the submission of the current version of the manuscript.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par88">Nicolas Weiss perceived consultant fees from Owkin and Alexion. Cl&#x000e9;mence Marois perceived consultant fees from UCB.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Yuki</surname><given-names>N</given-names></name><name><surname>Hartung</surname><given-names>HP</given-names></name></person-group><article-title>Guillain-Barr&#x000e9; syndrome</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><issue>24</issue><fpage>2294</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1114525</pub-id><pub-id pub-id-type="pmid">22694000</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Yuki N, Hartung HP. Guillain-Barr&#x000e9; syndrome. N Engl J Med. 2012;366(24):2294&#x02013;304.<pub-id pub-id-type="pmid">22694000</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Willison</surname><given-names>HJ</given-names></name><name><surname>Jacobs</surname><given-names>BC</given-names></name><name><surname>van Doorn</surname><given-names>PA</given-names></name></person-group><article-title>Guillain-Barr&#x000e9; syndrome</article-title><source>Lancet</source><year>2016</year><volume>388</volume><issue>10045</issue><fpage>717</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)00339-1</pub-id><pub-id pub-id-type="pmid">26948435</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barr&#x000e9; syndrome. Lancet. 2016;388(10045):717&#x02013;27.<pub-id pub-id-type="pmid">26948435</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Sejvar</surname><given-names>JJ</given-names></name><name><surname>Baughman</surname><given-names>AL</given-names></name><name><surname>Wise</surname><given-names>M</given-names></name><name><surname>Morgan</surname><given-names>OW</given-names></name></person-group><article-title>Population incidence of Guillain-Barr&#x000e9; syndrome: a systematic review and meta-analysis</article-title><source>Neuroepidemiology</source><year>2011</year><volume>36</volume><issue>2</issue><fpage>123</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1159/000324710</pub-id><pub-id pub-id-type="pmid">21422765</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barr&#x000e9; syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36(2):123&#x02013;33.<pub-id pub-id-type="pmid">21422765</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>JL</given-names></name><name><surname>Sheikh</surname><given-names>KA</given-names></name><name><surname>Wu</surname><given-names>HS</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>ZF</given-names></name><name><surname>Cornblath</surname><given-names>DR</given-names></name><etal/></person-group><article-title>Physiologic-pathologic correlation in Guillain-Barr&#x000e9; syndrome in children</article-title><source>Neurology</source><year>2000</year><volume>54</volume><issue>1</issue><fpage>33</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1212/WNL.54.1.33</pub-id><pub-id pub-id-type="pmid">10636122</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Lu JL, Sheikh KA, Wu HS, Zhang J, Jiang ZF, Cornblath DR, et al. Physiologic-pathologic correlation in Guillain-Barr&#x000e9; syndrome in children. Neurology. 2000;54(1):33&#x02013;9.<pub-id pub-id-type="pmid">10636122</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">Guillain G, Barr&#x000e9; J, Strohl A. Sur Un syndromede radiculo-n&#x000e9;vrite avec hyperalbuminose du Liquide C&#x000e9;phalorachidien Sans r&#x000e9;action cellulaire. Remarques Sur les caract&#x000e8;res cliniques et graphiques des r&#x000e9;flexes tendineux. Bull et Mem de la Soc M&#x000e9;d des Hop de Paris. 1916;1462&#x02013;70.</mixed-citation></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Goodfellow</surname><given-names>JA</given-names></name><name><surname>Willison</surname><given-names>HJ</given-names></name></person-group><article-title>Guillain-Barr&#x000e9; syndrome: a century of progress</article-title><source>Nat Rev Neurol</source><year>2016</year><volume>12</volume><issue>12</issue><fpage>723</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2016.172</pub-id><pub-id pub-id-type="pmid">27857121</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Goodfellow JA, Willison HJ. Guillain-Barr&#x000e9; syndrome: a century of progress. Nat Rev Neurol. 2016;12(12):723&#x02013;31.<pub-id pub-id-type="pmid">27857121</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobs</surname><given-names>BC</given-names></name><name><surname>Rothbarth</surname><given-names>PH</given-names></name><name><surname>van der Mech&#x000e9;</surname><given-names>FG</given-names></name><name><surname>Herbrink</surname><given-names>P</given-names></name><name><surname>Schmitz</surname><given-names>PI</given-names></name><name><surname>de Klerk</surname><given-names>MA</given-names></name><etal/></person-group><article-title>The spectrum of antecedent infections in Guillain-Barr&#x000e9; syndrome: a case-control study</article-title><source>Neurology</source><year>1998</year><volume>51</volume><issue>4</issue><fpage>1110</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1212/WNL.51.4.1110</pub-id><pub-id pub-id-type="pmid">9781538</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Jacobs BC, Rothbarth PH, van der Mech&#x000e9; FG, Herbrink P, Schmitz PI, de Klerk MA, et al. The spectrum of antecedent infections in Guillain-Barr&#x000e9; syndrome: a case-control study. Neurology. 1998;51(4):1110&#x02013;5.<pub-id pub-id-type="pmid">9781538</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>TW</given-names></name><name><surname>Willison</surname><given-names>HJ</given-names></name><name><surname>Nachamkin</surname><given-names>I</given-names></name><name><surname>Li</surname><given-names>CY</given-names></name><name><surname>Veitch</surname><given-names>J</given-names></name><name><surname>Ung</surname><given-names>H</given-names></name><etal/></person-group><article-title>Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barr&#x000e9; syndrome</article-title><source>Ann Neurol</source><year>1999</year><volume>45</volume><issue>2</issue><fpage>168</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1002/1531-8249(199902)45:2&#x0003c;168::AID-ANA6&#x0003e;3.0.CO;2-6</pub-id><pub-id pub-id-type="pmid">9989618</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Ho TW, Willison HJ, Nachamkin I, Li CY, Veitch J, Ung H, et al. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barr&#x000e9; syndrome. Ann Neurol. 1999;45(2):168&#x02013;73.<pub-id pub-id-type="pmid">9989618</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Huizinga</surname><given-names>R</given-names></name><name><surname>van den Berg</surname><given-names>B</given-names></name><name><surname>van Rijs</surname><given-names>W</given-names></name><name><surname>Tio-Gillen</surname><given-names>AP</given-names></name><name><surname>Fokkink</surname><given-names>WJR</given-names></name><name><surname>Bakker-Jonges</surname><given-names>LE</given-names></name><etal/></person-group><article-title>Innate immunity to Campylobacter jejuni in Guillain-Barr&#x000e9; syndrome</article-title><source>Ann Neurol</source><year>2015</year><volume>78</volume><issue>3</issue><fpage>343</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1002/ana.24442</pub-id><pub-id pub-id-type="pmid">26017721</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Huizinga R, van den Berg B, van Rijs W, Tio-Gillen AP, Fokkink WJR, Bakker-Jonges LE, et al. Innate immunity to Campylobacter jejuni in Guillain-Barr&#x000e9; syndrome. Ann Neurol. 2015;78(3):343&#x02013;54.<pub-id pub-id-type="pmid">26017721</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>N</given-names></name><name><surname>Andersson</surname><given-names>Y</given-names></name><name><surname>Jormanainen</surname><given-names>V</given-names></name><name><surname>Gustavsson</surname><given-names>O</given-names></name><name><surname>Giesecke</surname><given-names>J</given-names></name></person-group><article-title>The risk of Guillain-Barr&#x000e9; syndrome following infection with Campylobacter jejuni</article-title><source>Epidemiol Infect</source><year>1999</year><volume>122</volume><issue>1</issue><fpage>15</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1017/S0950268898001861</pub-id><pub-id pub-id-type="pmid">10098780</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">McCarthy N, Andersson Y, Jormanainen V, Gustavsson O, Giesecke J. The risk of Guillain-Barr&#x000e9; syndrome following infection with Campylobacter jejuni. Epidemiol Infect. 1999;122(1):15&#x02013;7.<pub-id pub-id-type="pmid">10098780</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>M</given-names></name><name><surname>Kuwabara</surname><given-names>S</given-names></name><name><surname>Miyake</surname><given-names>M</given-names></name><name><surname>Noda</surname><given-names>M</given-names></name><name><surname>Kuroki</surname><given-names>H</given-names></name><name><surname>Kanno</surname><given-names>H</given-names></name><etal/></person-group><article-title>Haemophilus influenzae infection and Guillain-Barr&#x000e9; syndrome</article-title><source>Brain</source><year>2000</year><volume>123</volume><issue>Pt 10</issue><fpage>2171</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1093/brain/123.10.2171</pub-id><pub-id pub-id-type="pmid">11004133</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Mori M, Kuwabara S, Miyake M, Noda M, Kuroki H, Kanno H, et al. Haemophilus influenzae infection and Guillain-Barr&#x000e9; syndrome. Brain. 2000;123(Pt 10):2171&#x02013;8.<pub-id pub-id-type="pmid">11004133</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Grimaldi-Bensouda</surname><given-names>L</given-names></name><name><surname>Alp&#x000e9;rovitch</surname><given-names>A</given-names></name><name><surname>Besson</surname><given-names>G</given-names></name><name><surname>Vial</surname><given-names>C</given-names></name><name><surname>Cuisset</surname><given-names>JM</given-names></name><name><surname>Papeix</surname><given-names>C</given-names></name><etal/></person-group><article-title>Guillain-Barre syndrome, influenzalike illnesses, and influenza vaccination during seasons with and without Circulating A/H1N1 viruses</article-title><source>Am J Epidemiol</source><year>2011</year><volume>174</volume><issue>3</issue><fpage>326</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1093/aje/kwr072</pub-id><pub-id pub-id-type="pmid">21652600</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Grimaldi-Bensouda L, Alp&#x000e9;rovitch A, Besson G, Vial C, Cuisset JM, Papeix C, et al. Guillain-Barre syndrome, influenzalike illnesses, and influenza vaccination during seasons with and without Circulating A/H1N1 viruses. Am J Epidemiol. 2011;174(3):326&#x02013;35.<pub-id pub-id-type="pmid">21652600</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>van den Berg</surname><given-names>B</given-names></name><name><surname>van der Eijk</surname><given-names>AA</given-names></name><name><surname>Pas</surname><given-names>SD</given-names></name><name><surname>Hunter</surname><given-names>JG</given-names></name><name><surname>Madden</surname><given-names>RG</given-names></name><name><surname>Tio-Gillen</surname><given-names>AP</given-names></name><etal/></person-group><article-title>Guillain-Barr&#x000e9; syndrome associated with preceding hepatitis E virus infection</article-title><source>Neurology</source><year>2014</year><volume>82</volume><issue>6</issue><fpage>491</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000000111</pub-id><pub-id pub-id-type="pmid">24415572</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">van den Berg B, van der Eijk AA, Pas SD, Hunter JG, Madden RG, Tio-Gillen AP, et al. Guillain-Barr&#x000e9; syndrome associated with preceding hepatitis E virus infection. Neurology. 2014;82(6):491&#x02013;7.<pub-id pub-id-type="pmid">24415572</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Cao-Lormeau</surname><given-names>VM</given-names></name><name><surname>Blake</surname><given-names>A</given-names></name><name><surname>Mons</surname><given-names>S</given-names></name><name><surname>Last&#x000e8;re</surname><given-names>S</given-names></name><name><surname>Roche</surname><given-names>C</given-names></name><name><surname>Vanhomwegen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Guillain-Barr&#x000e9; syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study</article-title><source>Lancet</source><year>2016</year><volume>387</volume><issue>10027</issue><fpage>1531</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)00562-6</pub-id><pub-id pub-id-type="pmid">26948433</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Cao-Lormeau VM, Blake A, Mons S, Last&#x000e8;re S, Roche C, Vanhomwegen J, et al. Guillain-Barr&#x000e9; syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016;387(10027):1531&#x02013;9.<pub-id pub-id-type="pmid">26948433</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Stegmann-Planchard</surname><given-names>S</given-names></name><name><surname>Gallian</surname><given-names>P</given-names></name><name><surname>Tressi&#x000e8;res</surname><given-names>B</given-names></name><name><surname>Leparc-Goffart</surname><given-names>I</given-names></name><name><surname>Lannuzel</surname><given-names>A</given-names></name><name><surname>Signat&#x000e9;</surname><given-names>A</given-names></name><etal/></person-group><article-title>Chikungunya, a risk factor for Guillain-Barr&#x000e9; syndrome</article-title><source>Clin Infect Dis</source><year>2020</year><volume>70</volume><issue>6</issue><fpage>1233</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1093/cid/ciz625</pub-id><pub-id pub-id-type="pmid">31290540</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Stegmann-Planchard S, Gallian P, Tressi&#x000e8;res B, Leparc-Goffart I, Lannuzel A, Signat&#x000e9; A, et al. Chikungunya, a risk factor for Guillain-Barr&#x000e9; syndrome. Clin Infect Dis. 2020;70(6):1233&#x02013;5.<pub-id pub-id-type="pmid">31290540</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Frontera JA, Tamborska AA, Doheim MF, Garcia-Azorin D, Gezegen H, Guekht A et al. Neurological Events Reported after COVID-19 Vaccines: An Analysis of VAERS. Ann Neurol. 2022.</mixed-citation></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Kao</surname><given-names>JC</given-names></name><name><surname>Liao</surname><given-names>B</given-names></name><name><surname>Markovic</surname><given-names>SN</given-names></name><name><surname>Klein</surname><given-names>CJ</given-names></name><name><surname>Naddaf</surname><given-names>E</given-names></name><name><surname>Staff</surname><given-names>NP</given-names></name><etal/></person-group><article-title>Neurological complications associated with Anti-Programmed death 1 (PD-1) antibodies</article-title><source>JAMA Neurol</source><year>2017</year><volume>74</volume><issue>10</issue><fpage>1216</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2017.1912</pub-id><pub-id pub-id-type="pmid">28873125</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP, et al. Neurological complications associated with Anti-Programmed death 1 (PD-1) antibodies. JAMA Neurol. 2017;74(10):1216&#x02013;22.<pub-id pub-id-type="pmid">28873125</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Pappa</surname><given-names>E</given-names></name><name><surname>Berzero</surname><given-names>G</given-names></name><name><surname>Herlin</surname><given-names>B</given-names></name><name><surname>Ricard</surname><given-names>D</given-names></name><name><surname>Tafani</surname><given-names>C</given-names></name><name><surname>Devic</surname><given-names>P</given-names></name><etal/></person-group><article-title>Guillain-Barr&#x000e9; syndrome during Platinum-Based chemotherapy: A case series and review of the literature</article-title><source>Oncologist</source><year>2020</year><volume>25</volume><issue>1</issue><fpage>e194</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2019-0255</pub-id><pub-id pub-id-type="pmid">31615948</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Pappa E, Berzero G, Herlin B, Ricard D, Tafani C, Devic P, et al. Guillain-Barr&#x000e9; syndrome during Platinum-Based chemotherapy: A case series and review of the literature. Oncologist. 2020;25(1):e194&#x02013;7.<pub-id pub-id-type="pmid">31615948</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Rudant</surname><given-names>J</given-names></name><name><surname>Dupont</surname><given-names>A</given-names></name><name><surname>Mikaeloff</surname><given-names>Y</given-names></name><name><surname>Bolgert</surname><given-names>F</given-names></name><name><surname>Coste</surname><given-names>J</given-names></name><name><surname>Weill</surname><given-names>A</given-names></name></person-group><article-title>Surgery and risk of Guillain-Barr&#x000e9; syndrome: A French nationwide epidemiologic study</article-title><source>Neurology</source><year>2018</year><volume>91</volume><issue>13</issue><fpage>e1220</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000006246</pub-id><pub-id pub-id-type="pmid">30143563</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Rudant J, Dupont A, Mikaeloff Y, Bolgert F, Coste J, Weill A. Surgery and risk of Guillain-Barr&#x000e9; syndrome: A French nationwide epidemiologic study. Neurology. 2018;91(13):e1220&#x02013;7.<pub-id pub-id-type="pmid">30143563</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Kaida</surname><given-names>Kichi</given-names></name><name><surname>Morita</surname><given-names>D</given-names></name><name><surname>Kanzaki</surname><given-names>M</given-names></name><name><surname>Kamakura</surname><given-names>K</given-names></name><name><surname>Motoyoshi</surname><given-names>K</given-names></name><name><surname>Hirakawa</surname><given-names>M</given-names></name><etal/></person-group><article-title>Ganglioside complexes as new target antigens in Guillain-Barr&#x000e9; syndrome</article-title><source>Ann Neurol</source><year>2004</year><volume>56</volume><issue>4</issue><fpage>567</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1002/ana.20222</pub-id><pub-id pub-id-type="pmid">15389898</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Kaida Kichi, Morita D, Kanzaki M, Kamakura K, Motoyoshi K, Hirakawa M, et al. Ganglioside complexes as new target antigens in Guillain-Barr&#x000e9; syndrome. Ann Neurol. 2004;56(4):567&#x02013;71.<pub-id pub-id-type="pmid">15389898</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Yuki</surname><given-names>N</given-names></name><name><surname>Yoshino</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Miyatake</surname><given-names>T</given-names></name></person-group><article-title>Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis</article-title><source>Neurology</source><year>1990</year><volume>40</volume><issue>12</issue><fpage>1900</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1212/WNL.40.12.1900</pub-id><pub-id pub-id-type="pmid">2247243</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Yuki N, Yoshino H, Sato S, Miyatake T. Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology. 1990;40(12):1900&#x02013;2.<pub-id pub-id-type="pmid">2247243</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Yuki</surname><given-names>N</given-names></name><name><surname>Yoshino</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Shinozawa</surname><given-names>K</given-names></name><name><surname>Miyatake</surname><given-names>T</given-names></name></person-group><article-title>Severe acute axonal form of Guillain-Barr&#x000e9; syndrome associated with IgG anti-GD1a antibodies</article-title><source>Muscle Nerve</source><year>1992</year><volume>15</volume><issue>8</issue><fpage>899</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1002/mus.880150806</pub-id><pub-id pub-id-type="pmid">1495505</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Yuki N, Yoshino H, Sato S, Shinozawa K, Miyatake T. Severe acute axonal form of Guillain-Barr&#x000e9; syndrome associated with IgG anti-GD1a antibodies. Muscle Nerve. 1992;15(8):899&#x02013;903.<pub-id pub-id-type="pmid">1495505</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Yuki</surname><given-names>N</given-names></name><name><surname>Taki</surname><given-names>T</given-names></name><name><surname>Inagaki</surname><given-names>F</given-names></name><name><surname>Kasama</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Saito</surname><given-names>K</given-names></name><etal/></person-group><article-title>A bacterium lipopolysaccharide that elicits Guillain-Barr&#x000e9; syndrome has a GM1 ganglioside-like structure</article-title><source>J Exp Med</source><year>1993</year><volume>178</volume><issue>5</issue><fpage>1771</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1084/jem.178.5.1771</pub-id><pub-id pub-id-type="pmid">8228822</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Yuki N, Taki T, Inagaki F, Kasama T, Takahashi M, Saito K, et al. A bacterium lipopolysaccharide that elicits Guillain-Barr&#x000e9; syndrome has a GM1 ganglioside-like structure. J Exp Med. 1993;178(5):1771&#x02013;5.<pub-id pub-id-type="pmid">8228822</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Rees</surname><given-names>JH</given-names></name><name><surname>Soudain</surname><given-names>SE</given-names></name><name><surname>Gregson</surname><given-names>NA</given-names></name><name><surname>Hughes</surname><given-names>RA</given-names></name></person-group><article-title>Campylobacter jejuni infection and Guillain-Barr&#x000e9; syndrome</article-title><source>N Engl J Med</source><year>1995</year><volume>333</volume><issue>21</issue><fpage>1374</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1056/NEJM199511233332102</pub-id><pub-id pub-id-type="pmid">7477117</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Rees JH, Soudain SE, Gregson NA, Hughes RA. Campylobacter jejuni infection and Guillain-Barr&#x000e9; syndrome. N Engl J Med. 1995;333(21):1374&#x02013;9.<pub-id pub-id-type="pmid">7477117</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Kusunoki</surname><given-names>S</given-names></name><name><surname>Shiina</surname><given-names>M</given-names></name><name><surname>Kanazawa</surname><given-names>I</given-names></name></person-group><article-title>Anti-Gal-C antibodies in GBS subsequent to Mycoplasma infection: evidence of molecular mimicry</article-title><source>Neurology</source><year>2001</year><volume>57</volume><issue>4</issue><fpage>736</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1212/WNL.57.4.736</pub-id><pub-id pub-id-type="pmid">11524496</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Kusunoki S, Shiina M, Kanazawa I. Anti-Gal-C antibodies in GBS subsequent to Mycoplasma infection: evidence of molecular mimicry. Neurology. 2001;57(4):736&#x02013;8.<pub-id pub-id-type="pmid">11524496</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Wanschitz</surname><given-names>J</given-names></name><name><surname>Maier</surname><given-names>H</given-names></name><name><surname>Lassmann</surname><given-names>H</given-names></name><name><surname>Budka</surname><given-names>H</given-names></name><name><surname>Berger</surname><given-names>T</given-names></name></person-group><article-title>Distinct time pattern of complement activation and cytotoxic T cell response in Guillain-Barr&#x000e9; syndrome</article-title><source>Brain</source><year>2003</year><volume>126</volume><issue>Pt 9</issue><fpage>2034</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1093/brain/awg207</pub-id><pub-id pub-id-type="pmid">12847075</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Wanschitz J, Maier H, Lassmann H, Budka H, Berger T. Distinct time pattern of complement activation and cytotoxic T cell response in Guillain-Barr&#x000e9; syndrome. Brain. 2003;126(Pt 9):2034&#x02013;42.<pub-id pub-id-type="pmid">12847075</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Koike</surname><given-names>H</given-names></name><name><surname>Katsuno</surname><given-names>M</given-names></name></person-group><article-title>Macrophages and autoantibodies in demyelinating diseases</article-title><source>Cells</source><year>2021</year><volume>10</volume><issue>4</issue><fpage>844</fpage><pub-id pub-id-type="doi">10.3390/cells10040844</pub-id><pub-id pub-id-type="pmid">33917929</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Koike H, Katsuno M. Macrophages and autoantibodies in demyelinating diseases. Cells. 2021;10(4):844.<pub-id pub-id-type="pmid">33917929</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Kokubun</surname><given-names>N</given-names></name><name><surname>Nishibayashi</surname><given-names>M</given-names></name><name><surname>Uncini</surname><given-names>A</given-names></name><name><surname>Odaka</surname><given-names>M</given-names></name><name><surname>Hirata</surname><given-names>K</given-names></name><name><surname>Yuki</surname><given-names>N</given-names></name></person-group><article-title>Conduction block in acute motor axonal neuropathy</article-title><source>Brain</source><year>2010</year><volume>133</volume><issue>10</issue><fpage>2897</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1093/brain/awq260</pub-id><pub-id pub-id-type="pmid">20855419</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Kokubun N, Nishibayashi M, Uncini A, Odaka M, Hirata K, Yuki N. Conduction block in acute motor axonal neuropathy. Brain. 2010;133(10):2897&#x02013;908.<pub-id pub-id-type="pmid">20855419</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Vucic</surname><given-names>S</given-names></name><name><surname>Cairns</surname><given-names>KD</given-names></name><name><surname>Black</surname><given-names>KR</given-names></name><name><surname>Chong</surname><given-names>PST</given-names></name><name><surname>Cros</surname><given-names>D</given-names></name></person-group><article-title>Neurophysiologic findings in early acute inflammatory demyelinating polyradiculoneuropathy</article-title><source>Clin Neurophysiol</source><year>2004</year><volume>115</volume><issue>10</issue><fpage>2329</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.clinph.2004.05.009</pub-id><pub-id pub-id-type="pmid">15351375</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Vucic S, Cairns KD, Black KR, Chong PST, Cros D. Neurophysiologic findings in early acute inflammatory demyelinating polyradiculoneuropathy. Clin Neurophysiol. 2004;115(10):2329&#x02013;35.<pub-id pub-id-type="pmid">15351375</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Cutillo</surname><given-names>G</given-names></name><name><surname>Saariaho</surname><given-names>AH</given-names></name><name><surname>Meri</surname><given-names>S</given-names></name></person-group><article-title>Physiology of gangliosides and the role of antiganglioside antibodies in human diseases</article-title><source>Cell Mol Immunol</source><year>2020</year><volume>17</volume><issue>4</issue><fpage>313</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1038/s41423-020-0388-9</pub-id><pub-id pub-id-type="pmid">32152553</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Cutillo G, Saariaho AH, Meri S. Physiology of gangliosides and the role of antiganglioside antibodies in human diseases. Cell Mol Immunol. 2020;17(4):313&#x02013;22.<pub-id pub-id-type="pmid">32152553</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Blum</surname><given-names>S</given-names></name><name><surname>McCombe</surname><given-names>PA</given-names></name></person-group><article-title>Genetics of Guillain-Barr&#x000e9; syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): current knowledge and future directions</article-title><source>J Peripher Nerv Syst</source><year>2014</year><volume>19</volume><issue>2</issue><fpage>88</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1111/jns5.12074</pub-id><pub-id pub-id-type="pmid">25039604</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Blum S, McCombe PA. Genetics of Guillain-Barr&#x000e9; syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): current knowledge and future directions. J Peripher Nerv Syst. 2014;19(2):88&#x02013;103.<pub-id pub-id-type="pmid">25039604</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Geleijns</surname><given-names>K</given-names></name><name><surname>Brouwer</surname><given-names>BA</given-names></name><name><surname>Jacobs</surname><given-names>BC</given-names></name><name><surname>Houwing-Duistermaat</surname><given-names>JJ</given-names></name><name><surname>van Duijn</surname><given-names>CM</given-names></name><name><surname>van Doorn</surname><given-names>PA</given-names></name></person-group><article-title>The occurrence of Guillain-Barre syndrome within families</article-title><source>Neurology</source><year>2004</year><volume>63</volume><issue>9</issue><fpage>1747</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000143055.09646.31</pub-id><pub-id pub-id-type="pmid">15534275</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Geleijns K, Brouwer BA, Jacobs BC, Houwing-Duistermaat JJ, van Duijn CM, van Doorn PA. The occurrence of Guillain-Barre syndrome within families. Neurology. 2004;63(9):1747&#x02013;50.<pub-id pub-id-type="pmid">15534275</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Khanmohammadi</surname><given-names>S</given-names></name><name><surname>Malekpour</surname><given-names>M</given-names></name><name><surname>Jabbari</surname><given-names>P</given-names></name><name><surname>Rezaei</surname><given-names>N</given-names></name></person-group><article-title>Genetic basis of Guillain-Barre syndrome</article-title><source>J Neuroimmunol</source><year>2021</year><volume>358</volume><fpage>577651</fpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2021.577651</pub-id><pub-id pub-id-type="pmid">34246981</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Khanmohammadi S, Malekpour M, Jabbari P, Rezaei N. Genetic basis of Guillain-Barre syndrome. J Neuroimmunol. 2021;358:577651.<pub-id pub-id-type="pmid">34246981</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Ramos</surname><given-names>AP</given-names></name><name><surname>Leonhard</surname><given-names>SE</given-names></name><name><surname>Halstead</surname><given-names>SK</given-names></name><name><surname>Cuba</surname><given-names>MA</given-names></name><name><surname>Casta&#x000f1;eda</surname><given-names>CC</given-names></name><name><surname>Dioses</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Guillain-Barr&#x000e9; syndrome outbreak in Peru 2019 associated with Campylobacter jejuni infection</article-title><source>Neurol Neuroimmunol Neuroinflamm</source><year>2021</year><volume>8</volume><issue>2</issue><fpage>e952</fpage><pub-id pub-id-type="doi">10.1212/NXI.0000000000000952</pub-id><pub-id pub-id-type="pmid">33547152</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Ramos AP, Leonhard SE, Halstead SK, Cuba MA, Casta&#x000f1;eda CC, Dioses JA, et al. Guillain-Barr&#x000e9; syndrome outbreak in Peru 2019 associated with Campylobacter jejuni infection. Neurol Neuroimmunol Neuroinflamm. 2021;8(2):e952.<pub-id pub-id-type="pmid">33547152</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">Guillain-Barr&#x000e9; outbreak in Peru. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/fr/emergencies/disease-outbreak-news/item/2023-DON477">https://www.who.int/fr/emergencies/disease-outbreak-news/item/2023-DON477</ext-link> (accessed August 8, 2024).</mixed-citation></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Wijdicks</surname><given-names>EF</given-names></name><name><surname>Ropper</surname><given-names>AH</given-names></name></person-group><article-title>Acute relapsing Guillain-Barr&#x000e9; syndrome after long asymptomatic intervals</article-title><source>Arch Neurol</source><year>1990</year><volume>47</volume><issue>1</issue><fpage>82</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1001/archneur.1990.00530010104027</pub-id><pub-id pub-id-type="pmid">2294897</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Wijdicks EF, Ropper AH. Acute relapsing Guillain-Barr&#x000e9; syndrome after long asymptomatic intervals. Arch Neurol. 1990;47(1):82&#x02013;4.<pub-id pub-id-type="pmid">2294897</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Grand&#x02019;Maison</surname><given-names>F</given-names></name><name><surname>Feasby</surname><given-names>TE</given-names></name><name><surname>Hahn</surname><given-names>AF</given-names></name><name><surname>Koopman</surname><given-names>WJ</given-names></name></person-group><article-title>Recurrent Guillain-Barr&#x000e9; syndrome. Clinical and laboratory features</article-title><source>Brain</source><year>1992</year><volume>115</volume><issue>Pt 4</issue><fpage>1093</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1093/brain/115.4.1093</pub-id><pub-id pub-id-type="pmid">1393505</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Grand&#x02019;Maison F, Feasby TE, Hahn AF, Koopman WJ. Recurrent Guillain-Barr&#x000e9; syndrome. Clinical and laboratory features. Brain. 1992;115(4):1093&#x02013;106.<pub-id pub-id-type="pmid">1393505</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Jamall</surname><given-names>S</given-names></name><name><surname>Baker</surname><given-names>N</given-names></name><name><surname>Peterson</surname><given-names>G</given-names></name><name><surname>Tsao</surname><given-names>B</given-names></name><name><surname>Rosenfeld</surname><given-names>J</given-names></name></person-group><article-title>Aggressive acquired demyelinating neuropathy caused by NF-155: initially Treatment-Resistant</article-title><source>J Clin Neuromuscul Dis</source><year>2023</year><volume>25</volume><issue>2</issue><fpage>59</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1097/CND.0000000000000464</pub-id><pub-id pub-id-type="pmid">37962191</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Jamall S, Baker N, Peterson G, Tsao B, Rosenfeld J. Aggressive acquired demyelinating neuropathy caused by NF-155: initially Treatment-Resistant. J Clin Neuromuscul Dis. 2023;25(2):59&#x02013;62.<pub-id pub-id-type="pmid">37962191</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Appeltshauser</surname><given-names>L</given-names></name><name><surname>Junghof</surname><given-names>H</given-names></name><name><surname>Messinger</surname><given-names>J</given-names></name><name><surname>Linke</surname><given-names>J</given-names></name><name><surname>Haarmann</surname><given-names>A</given-names></name><name><surname>Ayzenberg</surname><given-names>I</given-names></name><etal/></person-group><article-title>Anti-pan-neurofascin antibodies induce subclass-related complement activation and nodo-paranodal damage</article-title><source>Brain</source><year>2023</year><volume>146</volume><issue>5</issue><fpage>1932</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1093/brain/awac418</pub-id><pub-id pub-id-type="pmid">36346134</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Appeltshauser L, Junghof H, Messinger J, Linke J, Haarmann A, Ayzenberg I, et al. Anti-pan-neurofascin antibodies induce subclass-related complement activation and nodo-paranodal damage. Brain. 2023;146(5):1932&#x02013;49.<pub-id pub-id-type="pmid">36346134</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Devaux</surname><given-names>JJ</given-names></name><name><surname>Odaka</surname><given-names>M</given-names></name><name><surname>Yuki</surname><given-names>N</given-names></name></person-group><article-title>Nodal proteins are target antigens in Guillain-Barr&#x000e9; syndrome</article-title><source>J Peripher Nerv Syst</source><year>2012</year><volume>17</volume><issue>1</issue><fpage>62</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1111/j.1529-8027.2012.00372.x</pub-id><pub-id pub-id-type="pmid">22462667</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Devaux JJ, Odaka M, Yuki N. Nodal proteins are target antigens in Guillain-Barr&#x000e9; syndrome. J Peripher Nerv Syst. 2012;17(1):62&#x02013;71.<pub-id pub-id-type="pmid">22462667</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Pascual-Go&#x000f1;i</surname><given-names>E</given-names></name><name><surname>Caballero-&#x000c1;vila</surname><given-names>M</given-names></name><name><surname>Querol</surname><given-names>L</given-names></name></person-group><article-title>Antibodies in autoimmune neuropathies: what to test, how to test, why to test</article-title><source>Neurology</source><year>2024</year><volume>103</volume><issue>4</issue><fpage>e209725</fpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000209725</pub-id><pub-id pub-id-type="pmid">39088795</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Pascual-Go&#x000f1;i E, Caballero-&#x000c1;vila M, Querol L. Antibodies in autoimmune neuropathies: what to test, how to test, why to test. Neurology. 2024;103(4):e209725.<pub-id pub-id-type="pmid">39088795</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>van Doorn</surname><given-names>PA</given-names></name><name><surname>Van den Bergh</surname><given-names>PYK</given-names></name><name><surname>Hadden</surname><given-names>RDM</given-names></name><name><surname>Avau</surname><given-names>B</given-names></name><name><surname>Vankrunkelsven</surname><given-names>P</given-names></name><name><surname>Attarian</surname><given-names>S</given-names></name><etal/></person-group><article-title>European academy of neurology/peripheral nerve society guideline on diagnosis and treatment of Guillain-Barr&#x000e9; syndrome</article-title><source>Eur J Neurol</source><year>2023</year><volume>30</volume><issue>12</issue><fpage>3646</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1111/ene.16073</pub-id><pub-id pub-id-type="pmid">37814552</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">van Doorn PA, Van den Bergh PYK, Hadden RDM, Avau B, Vankrunkelsven P, Attarian S, et al. European academy of neurology/peripheral nerve society guideline on diagnosis and treatment of Guillain-Barr&#x000e9; syndrome. Eur J Neurol. 2023;30(12):3646&#x02013;74.<pub-id pub-id-type="pmid">37814552</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Rajabally</surname><given-names>YA</given-names></name><name><surname>Uncini</surname><given-names>A</given-names></name></person-group><article-title>Outcome and its predictors in Guillain-Barre syndrome</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2012</year><volume>83</volume><issue>7</issue><fpage>711</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2011-301882</pub-id><pub-id pub-id-type="pmid">22566597</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Rajabally YA, Uncini A. Outcome and its predictors in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 2012;83(7):711&#x02013;8.<pub-id pub-id-type="pmid">22566597</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Le Guennec</surname><given-names>L</given-names></name><name><surname>Brisset</surname><given-names>M</given-names></name><name><surname>Viala</surname><given-names>K</given-names></name><name><surname>Essardy</surname><given-names>F</given-names></name><name><surname>Maisonobe</surname><given-names>T</given-names></name><name><surname>Rohaut</surname><given-names>B</given-names></name><etal/></person-group><article-title>Post-traumatic stress symptoms in Guillain-Barr&#x000e9; syndrome patients after prolonged mechanical ventilation in ICU: a preliminary report</article-title><source>J Peripher Nerv Syst</source><year>2014</year><volume>19</volume><issue>3</issue><fpage>218</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1111/jns.12087</pub-id><pub-id pub-id-type="pmid">25403788</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Le Guennec L, Brisset M, Viala K, Essardy F, Maisonobe T, Rohaut B, et al. Post-traumatic stress symptoms in Guillain-Barr&#x000e9; syndrome patients after prolonged mechanical ventilation in ICU: a preliminary report. J Peripher Nerv Syst. 2014;19(3):218&#x02013;23.<pub-id pub-id-type="pmid">25403788</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Ropper</surname><given-names>AH</given-names></name></person-group><article-title>The Guillain-Barr&#x000e9; syndrome</article-title><source>N Engl J Med</source><year>1992</year><volume>326</volume><issue>17</issue><fpage>1130</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1056/NEJM199204233261706</pub-id><pub-id pub-id-type="pmid">1552914</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Ropper AH. The Guillain-Barr&#x000e9; syndrome. N Engl J Med. 1992;326(17):1130&#x02013;6.<pub-id pub-id-type="pmid">1552914</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Leonhard</surname><given-names>SE</given-names></name><name><surname>Mandarakas</surname><given-names>MR</given-names></name><name><surname>Gondim</surname><given-names>FAA</given-names></name><name><surname>Bateman</surname><given-names>K</given-names></name><name><surname>Ferreira</surname><given-names>MLB</given-names></name><name><surname>Cornblath</surname><given-names>DR</given-names></name><etal/></person-group><article-title>Diagnosis and management of Guillain-Barr&#x000e9; syndrome in ten steps</article-title><source>Nat Rev Neurol</source><year>2019</year><volume>15</volume><issue>11</issue><fpage>671</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1038/s41582-019-0250-9</pub-id><pub-id pub-id-type="pmid">31541214</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Leonhard SE, Mandarakas MR, Gondim FAA, Bateman K, Ferreira MLB, Cornblath DR, et al. Diagnosis and management of Guillain-Barr&#x000e9; syndrome in ten steps. Nat Rev Neurol. 2019;15(11):671&#x02013;83.<pub-id pub-id-type="pmid">31541214</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Ruts</surname><given-names>L</given-names></name><name><surname>van Koningsveld</surname><given-names>R</given-names></name><name><surname>van Doorn</surname><given-names>PA</given-names></name></person-group><article-title>Distinguishing acute-onset CIDP from Guillain-Barr&#x000e9; syndrome with treatment related fluctuations</article-title><source>Neurology</source><year>2005</year><volume>65</volume><issue>1</issue><fpage>138</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000167549.09664.b8</pub-id><pub-id pub-id-type="pmid">16009902</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Ruts L, van Koningsveld R, van Doorn PA. Distinguishing acute-onset CIDP from Guillain-Barr&#x000e9; syndrome with treatment related fluctuations. Neurology. 2005;65(1):138&#x02013;40.<pub-id pub-id-type="pmid">16009902</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Zaeem</surname><given-names>Z</given-names></name><name><surname>Siddiqi</surname><given-names>ZA</given-names></name><name><surname>Zochodne</surname><given-names>DW</given-names></name></person-group><article-title>Autonomic involvement in Guillain-Barr&#x000e9; syndrome: an update</article-title><source>Clin Auton Res</source><year>2019</year><volume>29</volume><issue>3</issue><fpage>289</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1007/s10286-018-0542-y</pub-id><pub-id pub-id-type="pmid">30019292</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Zaeem Z, Siddiqi ZA, Zochodne DW. Autonomic involvement in Guillain-Barr&#x000e9; syndrome: an update. Clin Auton Res. 2019;29(3):289&#x02013;99.<pub-id pub-id-type="pmid">30019292</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Chakraborty</surname><given-names>T</given-names></name><name><surname>Kramer</surname><given-names>CL</given-names></name><name><surname>Wijdicks</surname><given-names>EFM</given-names></name><name><surname>Rabinstein</surname><given-names>AA</given-names></name></person-group><article-title>Dysautonomia in Guillain-Barr&#x000e9; syndrome: prevalence, clinical spectrum, and outcomes</article-title><source>Neurocrit Care</source><year>2020</year><volume>32</volume><issue>1</issue><fpage>113</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1007/s12028-019-00781-w</pub-id><pub-id pub-id-type="pmid">31297663</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Chakraborty T, Kramer CL, Wijdicks EFM, Rabinstein AA. Dysautonomia in Guillain-Barr&#x000e9; syndrome: prevalence, clinical spectrum, and outcomes. Neurocrit Care. 2020;32(1):113&#x02013;20.<pub-id pub-id-type="pmid">31297663</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Ruts</surname><given-names>L</given-names></name><name><surname>Drenthen</surname><given-names>J</given-names></name><name><surname>Jongen</surname><given-names>JLM</given-names></name><name><surname>Hop</surname><given-names>WCJ</given-names></name><name><surname>Visser</surname><given-names>GH</given-names></name><name><surname>Jacobs</surname><given-names>BC</given-names></name><etal/></person-group><article-title>Pain in Guillain-Barre syndrome: a long-term follow-up study</article-title><source>Neurology</source><year>2010</year><volume>75</volume><issue>16</issue><fpage>1439</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181f88345</pub-id><pub-id pub-id-type="pmid">20861454</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Ruts L, Drenthen J, Jongen JLM, Hop WCJ, Visser GH, Jacobs BC, et al. Pain in Guillain-Barre syndrome: a long-term follow-up study. Neurology. 2010;75(16):1439&#x02013;47.<pub-id pub-id-type="pmid">20861454</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Korinthenberg</surname><given-names>R</given-names></name><name><surname>Eckenweiler</surname><given-names>M</given-names></name><name><surname>Fuchs</surname><given-names>H</given-names></name></person-group><article-title>Severe Locked-In-Like Guillain-Barr&#x000e9;&#x02019;s syndrome: dilemmas in diagnosis and treatment</article-title><source>Neuropediatrics</source><year>2021</year><volume>52</volume><issue>1</issue><fpage>19</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1055/s-0040-1715480</pub-id><pub-id pub-id-type="pmid">33111302</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Korinthenberg R, Eckenweiler M, Fuchs H. Severe Locked-In-Like Guillain-Barr&#x000e9;&#x02019;s syndrome: dilemmas in diagnosis and treatment. Neuropediatrics. 2021;52(1):19&#x02013;26.<pub-id pub-id-type="pmid">33111302</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Faugeras</surname><given-names>F</given-names></name><name><surname>Rohaut</surname><given-names>B</given-names></name><name><surname>Weiss</surname><given-names>N</given-names></name><name><surname>Bekinschtein</surname><given-names>T</given-names></name><name><surname>Galanaud</surname><given-names>D</given-names></name><name><surname>Puybasset</surname><given-names>L</given-names></name><etal/></person-group><article-title>Event related potentials elicited by violations of auditory regularities in patients with impaired consciousness</article-title><source>Neuropsychologia</source><year>2012</year><volume>50</volume><issue>3</issue><fpage>403</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.neuropsychologia.2011.12.015</pub-id><pub-id pub-id-type="pmid">22230230</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Faugeras F, Rohaut B, Weiss N, Bekinschtein T, Galanaud D, Puybasset L, et al. Event related potentials elicited by violations of auditory regularities in patients with impaired consciousness. Neuropsychologia. 2012;50(3):403&#x02013;18.<pub-id pub-id-type="pmid">22230230</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Yuki</surname><given-names>N</given-names></name><name><surname>Kokubun</surname><given-names>N</given-names></name><name><surname>Kuwabara</surname><given-names>S</given-names></name><name><surname>Sekiguchi</surname><given-names>Y</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Odaka</surname><given-names>M</given-names></name><etal/></person-group><article-title>Guillain-Barr&#x000e9; syndrome associated with normal or exaggerated tendon reflexes</article-title><source>J Neurol</source><year>2012</year><volume>259</volume><issue>6</issue><fpage>1181</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1007/s00415-011-6330-4</pub-id><pub-id pub-id-type="pmid">22143612</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Yuki N, Kokubun N, Kuwabara S, Sekiguchi Y, Ito M, Odaka M, et al. Guillain-Barr&#x000e9; syndrome associated with normal or exaggerated tendon reflexes. J Neurol. 2012;259(6):1181&#x02013;90.<pub-id pub-id-type="pmid">22143612</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Wakerley</surname><given-names>BR</given-names></name><name><surname>Soon</surname><given-names>D</given-names></name><name><surname>Chan</surname><given-names>YC</given-names></name><name><surname>Yuki</surname><given-names>N</given-names></name></person-group><article-title>Atypical Bickerstaff brainstem encephalitis: ataxic hypersomnolence without ophthalmoplegia</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2013</year><volume>84</volume><issue>11</issue><fpage>1206</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2013-304993</pub-id><pub-id pub-id-type="pmid">23564757</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Wakerley BR, Soon D, Chan YC, Yuki N. Atypical Bickerstaff brainstem encephalitis: ataxic hypersomnolence without ophthalmoplegia. J Neurol Neurosurg Psychiatry. 2013;84(11):1206&#x02013;7.<pub-id pub-id-type="pmid">23564757</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Wakerley</surname><given-names>BR</given-names></name><name><surname>Yuki</surname><given-names>N</given-names></name></person-group><article-title>Polyneuritis cranialis&#x02013;subtype of Guillain-Barr&#x000e9; syndrome?</article-title><source>Nat Rev Neurol</source><year>2015</year><volume>11</volume><issue>11</issue><fpage>664</fpage><pub-id pub-id-type="doi">10.1038/nrneurol.2015.115</pub-id><pub-id pub-id-type="pmid">26369515</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Wakerley BR, Yuki N. Polyneuritis cranialis&#x02013;subtype of Guillain-Barr&#x000e9; syndrome? Nat Rev Neurol. 2015;11(11):664.<pub-id pub-id-type="pmid">26369515</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Wakerley</surname><given-names>BR</given-names></name><name><surname>Yuki</surname><given-names>N</given-names></name></person-group><article-title>Isolated facial diplegia in Guillain-Barr&#x000e9; syndrome: bifacial weakness with paresthesias</article-title><source>Muscle Nerve</source><year>2015</year><volume>52</volume><issue>6</issue><fpage>927</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1002/mus.24887</pub-id><pub-id pub-id-type="pmid">26315943</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Wakerley BR, Yuki N. Isolated facial diplegia in Guillain-Barr&#x000e9; syndrome: bifacial weakness with paresthesias. Muscle Nerve. 2015;52(6):927&#x02013;32.<pub-id pub-id-type="pmid">26315943</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Wakerley</surname><given-names>BR</given-names></name><name><surname>Yuki</surname><given-names>N</given-names></name></person-group><article-title>Pharyngeal-cervical-brachial variant of Guillain-Barre syndrome</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2014</year><volume>85</volume><issue>3</issue><fpage>339</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2013-305397</pub-id><pub-id pub-id-type="pmid">23804237</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Wakerley BR, Yuki N. Pharyngeal-cervical-brachial variant of Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 2014;85(3):339&#x02013;44.<pub-id pub-id-type="pmid">23804237</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Kimachi</surname><given-names>T</given-names></name><name><surname>Yuki</surname><given-names>N</given-names></name><name><surname>Kokubun</surname><given-names>N</given-names></name><name><surname>Yamaguchi</surname><given-names>S</given-names></name><name><surname>Wakerley</surname><given-names>BR</given-names></name></person-group><article-title>Paraparetic Guillain-Barr&#x000e9; syndrome: nondemyelinating reversible conduction failure restricted to the lower limbs</article-title><source>Muscle Nerve</source><year>2017</year><volume>55</volume><issue>2</issue><fpage>281</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1002/mus.25242</pub-id><pub-id pub-id-type="pmid">27397635</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Kimachi T, Yuki N, Kokubun N, Yamaguchi S, Wakerley BR. Paraparetic Guillain-Barr&#x000e9; syndrome: nondemyelinating reversible conduction failure restricted to the lower limbs. Muscle Nerve. 2017;55(2):281&#x02013;5.<pub-id pub-id-type="pmid">27397635</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Wakerley</surname><given-names>BR</given-names></name><name><surname>Uncini</surname><given-names>A</given-names></name><name><surname>Yuki</surname><given-names>N</given-names></name><collab>GBS Classification Group, GBS Classification Group</collab></person-group><article-title>Guillain-Barr&#x000e9; and miller fisher syndromes&#x02013;new diagnostic classification</article-title><source>Nat Rev Neurol</source><year>2014</year><volume>10</volume><issue>9</issue><fpage>537</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2014.138</pub-id><pub-id pub-id-type="pmid">25072194</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Wakerley BR, Uncini A, Yuki N, GBS Classification Group, GBS Classification Group. Guillain-Barr&#x000e9; and miller fisher syndromes&#x02013;new diagnostic classification. Nat Rev Neurol. 2014;10(9):537&#x02013;44.<pub-id pub-id-type="pmid">25072194</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Wakerley</surname><given-names>BR</given-names></name><name><surname>Yuki</surname><given-names>N</given-names></name></person-group><article-title>Mimics and chameleons in Guillain-Barr&#x000e9; and miller fisher syndromes</article-title><source>Pract Neurol</source><year>2015</year><volume>15</volume><issue>2</issue><fpage>90</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1136/practneurol-2014-000937</pub-id><pub-id pub-id-type="pmid">25239628</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Wakerley BR, Yuki N. Mimics and chameleons in Guillain-Barr&#x000e9; and miller fisher syndromes. Pract Neurol. 2015;15(2):90&#x02013;9.<pub-id pub-id-type="pmid">25239628</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Kuwabara</surname><given-names>S</given-names></name><name><surname>Misawa</surname><given-names>S</given-names></name><name><surname>Mori</surname><given-names>M</given-names></name></person-group><article-title>Is &#x02018;bickerstaff brainstem encephalitis&#x02019; really encephalitis?</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2013</year><volume>84</volume><issue>7</issue><fpage>712</fpage><pub-id pub-id-type="doi">10.1136/jnnp-2012-304655</pub-id><pub-id pub-id-type="pmid">23606734</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Kuwabara S, Misawa S, Mori M. Is &#x02018;bickerstaff brainstem encephalitis&#x02019; really encephalitis? J Neurol Neurosurg Psychiatry. 2013;84(7):712.<pub-id pub-id-type="pmid">23606734</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><collab>Criteria for diagnosis of Guillain-Barr&#x000e9; syndrome</collab></person-group><source>Ann Neurol</source><year>1978</year><volume>3</volume><issue>6</issue><fpage>565</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1002/ana.410030628</pub-id><pub-id pub-id-type="pmid">677829</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Criteria for diagnosis of Guillain-Barr&#x000e9; syndrome. Ann Neurol. 1978;3(6):565&#x02013;6.<pub-id pub-id-type="pmid">677829</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><mixed-citation publication-type="other">Asbury AK, Cornblath DR, Assessment of current diagnostic criteria for Guillain-Barr&#x000e9; syndrome. Ann Neurol. 1990;27Suppl:S21&#x02013;24.</mixed-citation></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Hadden</surname><given-names>RD</given-names></name><name><surname>Cornblath</surname><given-names>DR</given-names></name><name><surname>Hughes</surname><given-names>RA</given-names></name><name><surname>Zielasek</surname><given-names>J</given-names></name><name><surname>Hartung</surname><given-names>HP</given-names></name><name><surname>Toyka</surname><given-names>KV</given-names></name><etal/></person-group><article-title>Electrophysiological classification of Guillain-Barr&#x000e9; syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barr&#x000e9; syndrome trial group</article-title><source>Ann Neurol</source><year>1998</year><volume>44</volume><issue>5</issue><fpage>780</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1002/ana.410440512</pub-id><pub-id pub-id-type="pmid">9818934</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, et al. Electrophysiological classification of Guillain-Barr&#x000e9; syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barr&#x000e9; syndrome trial group. Ann Neurol. 1998;44(5):780&#x02013;8.<pub-id pub-id-type="pmid">9818934</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Arends</surname><given-names>S</given-names></name><name><surname>Drenthen</surname><given-names>J</given-names></name><name><surname>van den Bergh</surname><given-names>P</given-names></name><name><surname>Franssen</surname><given-names>H</given-names></name><name><surname>Hadden</surname><given-names>RDM</given-names></name><name><surname>Islam</surname><given-names>B</given-names></name><etal/></person-group><article-title>Electrodiagnosis of Guillain-Barre syndrome in the international GBS outcome study: differences in methods and reference values</article-title><source>Clin Neurophysiol</source><year>2022</year><volume>138</volume><fpage>231</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.clinph.2021.12.014</pub-id><pub-id pub-id-type="pmid">35078730</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Arends S, Drenthen J, van den Bergh P, Franssen H, Hadden RDM, Islam B, et al. Electrodiagnosis of Guillain-Barre syndrome in the international GBS outcome study: differences in methods and reference values. Clin Neurophysiol. 2022;138:231&#x02013;40.<pub-id pub-id-type="pmid">35078730</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Rajabally</surname><given-names>YA</given-names></name><name><surname>Durand</surname><given-names>MC</given-names></name><name><surname>Mitchell</surname><given-names>J</given-names></name><name><surname>Orlikowski</surname><given-names>D</given-names></name><name><surname>Nicolas</surname><given-names>G</given-names></name></person-group><article-title>Electrophysiological diagnosis of Guillain-Barr&#x000e9; syndrome subtype: could a single study suffice?</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2015</year><volume>86</volume><issue>1</issue><fpage>115</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2014-307815</pub-id><pub-id pub-id-type="pmid">24816419</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Rajabally YA, Durand MC, Mitchell J, Orlikowski D, Nicolas G. Electrophysiological diagnosis of Guillain-Barr&#x000e9; syndrome subtype: could a single study suffice? J Neurol Neurosurg Psychiatry. 2015;86(1):115&#x02013;9.<pub-id pub-id-type="pmid">24816419</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Fortanier</surname><given-names>E</given-names></name><name><surname>Berling</surname><given-names>E</given-names></name><name><surname>Zanin</surname><given-names>A</given-names></name><name><surname>Guillou</surname><given-names>AL</given-names></name><name><surname>Micaleff</surname><given-names>J</given-names></name><name><surname>Nicolas</surname><given-names>G</given-names></name><etal/></person-group><article-title>How to distinguish Guillain-Barr&#x000e9; syndrome from nitrous oxide-induced neuropathy: A 2-year, multicentric, retrospective study</article-title><source>Eur J Neurol</source><year>2023</year><volume>30</volume><issue>10</issue><fpage>3296</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1111/ene.15998</pub-id><pub-id pub-id-type="pmid">37494104</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Fortanier E, Berling E, Zanin A, Guillou AL, Micaleff J, Nicolas G, et al. How to distinguish Guillain-Barr&#x000e9; syndrome from nitrous oxide-induced neuropathy: A 2-year, multicentric, retrospective study. Eur J Neurol. 2023;30(10):3296&#x02013;306.<pub-id pub-id-type="pmid">37494104</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Dawudi</surname><given-names>Y</given-names></name><name><surname>Azoyan</surname><given-names>L</given-names></name><name><surname>Broucker</surname><given-names>TDE</given-names></name><name><surname>Gendre</surname><given-names>T</given-names></name><name><surname>Miloudi</surname><given-names>A</given-names></name><name><surname>Echaniz-Laguna</surname><given-names>A</given-names></name><etal/></person-group><article-title>Marked increase in severe neurological disorders after nitrous oxide abuse: a retrospective study in the greater Paris area</article-title><source>J Neurol</source><year>2024</year><volume>271</volume><issue>6</issue><fpage>3340</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1007/s00415-024-12264-w</pub-id><pub-id pub-id-type="pmid">38478030</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Dawudi Y, Azoyan L, Broucker TDE, Gendre T, Miloudi A, Echaniz-Laguna A, et al. Marked increase in severe neurological disorders after nitrous oxide abuse: a retrospective study in the greater Paris area. J Neurol. 2024;271(6):3340&#x02013;6.<pub-id pub-id-type="pmid">38478030</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Grimm</surname><given-names>A</given-names></name><name><surname>D&#x000e9;card</surname><given-names>BF</given-names></name><name><surname>Schramm</surname><given-names>A</given-names></name><name><surname>Pr&#x000f6;bstel</surname><given-names>AK</given-names></name><name><surname>Rasenack</surname><given-names>M</given-names></name><name><surname>Axer</surname><given-names>H</given-names></name><etal/></person-group><article-title>Ultrasound and electrophysiologic findings in patients with Guillain-Barr&#x000e9; syndrome at disease onset and over a period of six months</article-title><source>Clin Neurophysiol</source><year>2016</year><volume>127</volume><issue>2</issue><fpage>1657</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.clinph.2015.06.032</pub-id><pub-id pub-id-type="pmid">26220732</pub-id>
</element-citation><mixed-citation id="mc-CR69" publication-type="journal">Grimm A, D&#x000e9;card BF, Schramm A, Pr&#x000f6;bstel AK, Rasenack M, Axer H, et al. Ultrasound and electrophysiologic findings in patients with Guillain-Barr&#x000e9; syndrome at disease onset and over a period of six months. Clin Neurophysiol. 2016;127(2):1657&#x02013;63.<pub-id pub-id-type="pmid">26220732</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Razali</surname><given-names>SNO</given-names></name><name><surname>Arumugam</surname><given-names>T</given-names></name><name><surname>Yuki</surname><given-names>N</given-names></name><name><surname>Rozalli</surname><given-names>FI</given-names></name><name><surname>Goh</surname><given-names>KJ</given-names></name><name><surname>Shahrizaila</surname><given-names>N</given-names></name></person-group><article-title>Serial peripheral nerve ultrasound in Guillain-Barr&#x000e9; syndrome</article-title><source>Clin Neurophysiol</source><year>2016</year><volume>127</volume><issue>2</issue><fpage>1652</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.clinph.2015.06.030</pub-id><pub-id pub-id-type="pmid">26228791</pub-id>
</element-citation><mixed-citation id="mc-CR70" publication-type="journal">Razali SNO, Arumugam T, Yuki N, Rozalli FI, Goh KJ, Shahrizaila N. Serial peripheral nerve ultrasound in Guillain-Barr&#x000e9; syndrome. Clin Neurophysiol. 2016;127(2):1652&#x02013;6.<pub-id pub-id-type="pmid">26228791</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Altmann</surname><given-names>P</given-names></name><name><surname>De Simoni</surname><given-names>D</given-names></name><name><surname>Kaider</surname><given-names>A</given-names></name><name><surname>Ludwig</surname><given-names>B</given-names></name><name><surname>Rath</surname><given-names>J</given-names></name><name><surname>Leutmezer</surname><given-names>F</given-names></name><etal/></person-group><article-title>Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barr&#x000e9; syndrome</article-title><source>J Neuroinflammation</source><year>2020</year><volume>17</volume><issue>1</issue><fpage>86</fpage><pub-id pub-id-type="doi">10.1186/s12974-020-01737-0</pub-id><pub-id pub-id-type="pmid">32183837</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Altmann P, De Simoni D, Kaider A, Ludwig B, Rath J, Leutmezer F, et al. Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barr&#x000e9; syndrome. J Neuroinflammation. 2020;17(1):86.<pub-id pub-id-type="pmid">32183837</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><mixed-citation publication-type="other">Mart&#x000ed;n-Aguilar L, Camps-Renom P, Lleix&#x000e0; C, Pascual-Go&#x000f1;i E, D&#x000ed;az-Manera J, Rojas-Garc&#x000ed;a R et al. Serum neurofilament light chain predicts long-term prognosis in Guillain-Barr&#x000e9; syndrome patients. J Neurol Neurosurg Psychiatry. 2020;jnnp-2020-323899.</mixed-citation></ref><ref id="CR73"><label>73.</label><mixed-citation publication-type="other">Jacobs BC. Neurofilament light chain as biomarker for axonal damage in Guillain-Barr&#x000e9; syndrome. J Neurol Neurosurg Psychiatry. 2020;jnnp-2020-324308.</mixed-citation></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name><surname>Pfeiffer</surname><given-names>G</given-names></name><name><surname>Schiller</surname><given-names>B</given-names></name><name><surname>Kruse</surname><given-names>J</given-names></name><name><surname>Netzer</surname><given-names>J</given-names></name></person-group><article-title>Indicators of Dysautonomia in severe Guillain-Barr&#x000e9; syndrome</article-title><source>J Neurol</source><year>1999</year><volume>246</volume><issue>11</issue><fpage>1015</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1007/s004150050506</pub-id><pub-id pub-id-type="pmid">10631632</pub-id>
</element-citation><mixed-citation id="mc-CR74" publication-type="journal">Pfeiffer G, Schiller B, Kruse J, Netzer J. Indicators of Dysautonomia in severe Guillain-Barr&#x000e9; syndrome. J Neurol. 1999;246(11):1015&#x02013;22.<pub-id pub-id-type="pmid">10631632</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name><surname>de Jager</surname><given-names>AE</given-names></name><name><surname>Sluiter</surname><given-names>HJ</given-names></name></person-group><article-title>Clinical signs in severe Guillain-Barr&#x000e9; syndrome: analysis of 63 patients</article-title><source>J Neurol Sci</source><year>1991</year><volume>104</volume><issue>2</issue><fpage>143</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/0022-510X(91)90303-O</pub-id><pub-id pub-id-type="pmid">1940970</pub-id>
</element-citation><mixed-citation id="mc-CR75" publication-type="journal">de Jager AE, Sluiter HJ. Clinical signs in severe Guillain-Barr&#x000e9; syndrome: analysis of 63 patients. J Neurol Sci. 1991;104(2):143&#x02013;50.<pub-id pub-id-type="pmid">1940970</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>M</given-names></name><name><surname>Kalita</surname><given-names>J</given-names></name><name><surname>Misra</surname><given-names>UK</given-names></name></person-group><article-title>Renal salt wasting in Guillain-Barr&#x000e9; syndrome</article-title><source>Postgrad Med J</source><year>2019</year><volume>95</volume><issue>1129</issue><fpage>628</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1136/postgradmedj-2019-136870</pub-id><pub-id pub-id-type="pmid">31375556</pub-id>
</element-citation><mixed-citation id="mc-CR76" publication-type="journal">Kumar M, Kalita J, Misra UK. Renal salt wasting in Guillain-Barr&#x000e9; syndrome. Postgrad Med J. 2019;95(1129):628&#x02013;9.<pub-id pub-id-type="pmid">31375556</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>WC</given-names></name><name><surname>Green</surname><given-names>IJ</given-names></name><name><surname>Wang</surname><given-names>SP</given-names></name><name><surname>CEREBRAL SALT-WASTING ASSOCIATED</surname></name><collab>WITH THE GUILLAIN-BARR&#x02019;E SYNDROME</collab></person-group><source>Arch Intern Med</source><year>1965</year><volume>116</volume><fpage>113</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1001/archinte.1965.03870010115014</pub-id><pub-id pub-id-type="pmid">14338942</pub-id>
</element-citation><mixed-citation id="mc-CR77" publication-type="journal">Cooper WC, Green IJ, Wang SP, CEREBRAL SALT-WASTING ASSOCIATED, WITH THE GUILLAIN-BARR&#x02019;E SYNDROME. Arch Intern Med. 1965;116:113&#x02013;9.<pub-id pub-id-type="pmid">14338942</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name><surname>Lenhard</surname><given-names>T</given-names></name><name><surname>Grimm</surname><given-names>C</given-names></name><name><surname>Ringleb</surname><given-names>PA</given-names></name></person-group><article-title>Renal salt wasting as part of Dysautonomia in Guillain-Barre syndrome</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2011</year><volume>82</volume><issue>9</issue><fpage>1051</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2009.192369</pub-id><pub-id pub-id-type="pmid">20732865</pub-id>
</element-citation><mixed-citation id="mc-CR78" publication-type="journal">Lenhard T, Grimm C, Ringleb PA. Renal salt wasting as part of Dysautonomia in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 2011;82(9):1051&#x02013;3.<pub-id pub-id-type="pmid">20732865</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name><surname>Cochen</surname><given-names>V</given-names></name><name><surname>Arnulf</surname><given-names>I</given-names></name><name><surname>Demeret</surname><given-names>S</given-names></name><name><surname>Neulat</surname><given-names>ML</given-names></name><name><surname>Gourlet</surname><given-names>V</given-names></name><name><surname>Drouot</surname><given-names>X</given-names></name><etal/></person-group><article-title>Vivid Dreams, hallucinations, psychosis and REM sleep in Guillain-Barr&#x000e9; syndrome</article-title><source>Brain</source><year>2005</year><volume>128</volume><issue>Pt 11</issue><fpage>2535</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1093/brain/awh585</pub-id><pub-id pub-id-type="pmid">16000335</pub-id>
</element-citation><mixed-citation id="mc-CR79" publication-type="journal">Cochen V, Arnulf I, Demeret S, Neulat ML, Gourlet V, Drouot X, et al. Vivid Dreams, hallucinations, psychosis and REM sleep in Guillain-Barr&#x000e9; syndrome. Brain. 2005;128(Pt 11):2535&#x02013;45.<pub-id pub-id-type="pmid">16000335</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name><surname>Chevret</surname><given-names>S</given-names></name><name><surname>Hughes</surname><given-names>RA</given-names></name><name><surname>Annane</surname><given-names>D</given-names></name></person-group><article-title>Plasma exchange for Guillain-Barr&#x000e9; syndrome</article-title><source>Cochrane Database Syst Rev</source><year>2017</year><volume>2</volume><fpage>CD001798</fpage><pub-id pub-id-type="pmid">28241090</pub-id>
</element-citation><mixed-citation id="mc-CR80" publication-type="journal">Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barr&#x000e9; syndrome. Cochrane Database Syst Rev. 2017;2:CD001798.<pub-id pub-id-type="pmid">28241090</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><mixed-citation publication-type="other">Hughes RAC, Swan AV, van Doorn PA. Intravenous Immunoglobulin for Guillain-Barr&#x000e9; syndrome. Cochrane Database Syst Rev. 2014;(9):CD002063.</mixed-citation></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>RA</given-names></name><name><surname>Brassington</surname><given-names>R</given-names></name><name><surname>Gunn</surname><given-names>AA</given-names></name><name><surname>van Doorn</surname><given-names>PA</given-names></name></person-group><article-title>Corticosteroids for Guillain-Barr&#x000e9; syndrome</article-title><source>Cochrane Database Syst Rev</source><year>2016</year><volume>10</volume><fpage>CD001446</fpage><pub-id pub-id-type="pmid">27775812</pub-id>
</element-citation><mixed-citation id="mc-CR82" publication-type="journal">Hughes RA, Brassington R, Gunn AA, van Doorn PA. Corticosteroids for Guillain-Barr&#x000e9; syndrome. Cochrane Database Syst Rev. 2016;10:CD001446.<pub-id pub-id-type="pmid">27775812</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><collab>Appropriate number of plasma exchanges in Guillain-Barr&#x000e9; syndrome</collab></person-group><article-title>The French cooperative group on plasma exchange in Guillain-Barr&#x000e9; syndrome</article-title><source>Ann Neurol</source><year>1997</year><volume>41</volume><issue>3</issue><fpage>298</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1002/ana.410410304</pub-id><pub-id pub-id-type="pmid">9066350</pub-id>
</element-citation><mixed-citation id="mc-CR83" publication-type="journal">Appropriate number of plasma exchanges in Guillain-Barr&#x000e9; syndrome. The French cooperative group on plasma exchange in Guillain-Barr&#x000e9; syndrome. Ann Neurol. 1997;41(3):298&#x02013;306.<pub-id pub-id-type="pmid">9066350</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name><surname>Bouget</surname><given-names>J</given-names></name><name><surname>Chevret</surname><given-names>S</given-names></name><name><surname>Chastang</surname><given-names>C</given-names></name><name><surname>Raphael</surname><given-names>JC</given-names></name></person-group><article-title>Plasma exchange morbidity in Guillain-Barr&#x000e9; syndrome: results from the French prospective, randomized, multicenter study. The French cooperative group</article-title><source>Crit Care Med</source><year>1993</year><volume>21</volume><issue>5</issue><fpage>651</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1097/00003246-199305000-00006</pub-id><pub-id pub-id-type="pmid">8482086</pub-id>
</element-citation><mixed-citation id="mc-CR84" publication-type="journal">Bouget J, Chevret S, Chastang C, Raphael JC. Plasma exchange morbidity in Guillain-Barr&#x000e9; syndrome: results from the French prospective, randomized, multicenter study. The French cooperative group. Crit Care Med. 1993;21(5):651&#x02013;8.<pub-id pub-id-type="pmid">8482086</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name><surname>Korinthenberg</surname><given-names>R</given-names></name><name><surname>Schessl</surname><given-names>J</given-names></name><name><surname>Kirschner</surname><given-names>J</given-names></name><name><surname>M&#x000f6;nting</surname><given-names>JS</given-names></name></person-group><article-title>Intravenously administered Immunoglobulin in the treatment of childhood Guillain-Barr&#x000e9; syndrome: a randomized trial</article-title><source>Pediatrics</source><year>2005</year><volume>116</volume><issue>1</issue><fpage>8</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1542/peds.2004-1324</pub-id><pub-id pub-id-type="pmid">15995024</pub-id>
</element-citation><mixed-citation id="mc-CR85" publication-type="journal">Korinthenberg R, Schessl J, Kirschner J, M&#x000f6;nting JS. Intravenously administered Immunoglobulin in the treatment of childhood Guillain-Barr&#x000e9; syndrome: a randomized trial. Pediatrics. 2005;116(1):8&#x02013;14.<pub-id pub-id-type="pmid">15995024</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name><surname>Walgaard</surname><given-names>C</given-names></name><name><surname>Jacobs</surname><given-names>BC</given-names></name><name><surname>Lingsma</surname><given-names>HF</given-names></name><name><surname>Steyerberg</surname><given-names>EW</given-names></name><name><surname>van den Berg</surname><given-names>B</given-names></name><name><surname>Doets</surname><given-names>AY</given-names></name><etal/></person-group><article-title>Second intravenous Immunoglobulin dose in patients with Guillain-Barr&#x000e9; syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial</article-title><source>Lancet Neurol</source><year>2021</year><volume>20</volume><issue>4</issue><fpage>275</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(20)30494-4</pub-id><pub-id pub-id-type="pmid">33743237</pub-id>
</element-citation><mixed-citation id="mc-CR86" publication-type="journal">Walgaard C, Jacobs BC, Lingsma HF, Steyerberg EW, van den Berg B, Doets AY, et al. Second intravenous Immunoglobulin dose in patients with Guillain-Barr&#x000e9; syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2021;20(4):275&#x02013;83.<pub-id pub-id-type="pmid">33743237</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name><surname>Willison</surname><given-names>H</given-names></name><name><surname>Scherer</surname><given-names>SS</given-names></name></person-group><article-title>Ranvier revisited: novel nodal antigens stimulate interest in GBS pathogenesis</article-title><source>Neurology</source><year>2014</year><volume>83</volume><issue>2</issue><fpage>106</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000000581</pub-id><pub-id pub-id-type="pmid">24920859</pub-id>
</element-citation><mixed-citation id="mc-CR87" publication-type="journal">Willison H, Scherer SS. Ranvier revisited: novel nodal antigens stimulate interest in GBS pathogenesis. Neurology. 2014;83(2):106&#x02013;8.<pub-id pub-id-type="pmid">24920859</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name><surname>Savithri Nandeesha</surname><given-names>S</given-names></name><name><surname>Kasagga</surname><given-names>A</given-names></name><name><surname>Hawrami</surname><given-names>C</given-names></name><name><surname>Ricci</surname><given-names>E</given-names></name><name><surname>Hailu</surname><given-names>KT</given-names></name><name><surname>Salib</surname><given-names>K</given-names></name><etal/></person-group><article-title>Treatment efficacy of plasmapheresis versus intravenous Immunoglobulin in Guillain-Barr&#x000e9; syndrome management: A systematic review</article-title><source>Cureus</source><year>2024</year><volume>16</volume><issue>3</issue><fpage>e57066</fpage><pub-id pub-id-type="pmid">38681292</pub-id>
</element-citation><mixed-citation id="mc-CR88" publication-type="journal">Savithri Nandeesha S, Kasagga A, Hawrami C, Ricci E, Hailu KT, Salib K, et al. Treatment efficacy of plasmapheresis versus intravenous Immunoglobulin in Guillain-Barr&#x000e9; syndrome management: A systematic review. Cureus. 2024;16(3):e57066.<pub-id pub-id-type="pmid">38681292</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><collab>Randomised trial of</collab></person-group><article-title>Plasma exchange, intravenous Immunoglobulin, and combined treatments in Guillain-Barr&#x000e9; syndrome. Plasma Exchange/Sandoglobulin Guillain-Barr&#x000e9; syndrome trial group</article-title><source>Lancet</source><year>1997</year><volume>349</volume><issue>9047</issue><fpage>225</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(96)09095-2</pub-id><pub-id pub-id-type="pmid">9014908</pub-id>
</element-citation><mixed-citation id="mc-CR89" publication-type="journal">Randomised trial of. Plasma exchange, intravenous Immunoglobulin, and combined treatments in Guillain-Barr&#x000e9; syndrome. Plasma Exchange/Sandoglobulin Guillain-Barr&#x000e9; syndrome trial group. Lancet. 1997;349(9047):225&#x02013;30.<pub-id pub-id-type="pmid">9014908</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name><surname>Kleyweg</surname><given-names>RP</given-names></name><name><surname>van der Mech&#x000e9;</surname><given-names>FG</given-names></name></person-group><article-title>Treatment related fluctuations in Guillain-Barr&#x000e9; syndrome after high-dose Immunoglobulins or plasma-exchange</article-title><source>J Neurol Neurosurg Psychiatry</source><year>1991</year><volume>54</volume><issue>11</issue><fpage>957</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1136/jnnp.54.11.957</pub-id><pub-id pub-id-type="pmid">1800666</pub-id>
</element-citation><mixed-citation id="mc-CR90" publication-type="journal">Kleyweg RP, van der Mech&#x000e9; FG. Treatment related fluctuations in Guillain-Barr&#x000e9; syndrome after high-dose Immunoglobulins or plasma-exchange. J Neurol Neurosurg Psychiatry. 1991;54(11):957&#x02013;60.<pub-id pub-id-type="pmid">1800666</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name><surname>Lawn</surname><given-names>ND</given-names></name><name><surname>Fletcher</surname><given-names>DD</given-names></name><name><surname>Henderson</surname><given-names>RD</given-names></name><name><surname>Wolter</surname><given-names>TD</given-names></name><name><surname>Wijdicks</surname><given-names>EF</given-names></name></person-group><article-title>Anticipating mechanical ventilation in Guillain-Barr&#x000e9; syndrome</article-title><source>Arch Neurol</source><year>2001</year><volume>58</volume><issue>6</issue><fpage>893</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1001/archneur.58.6.893</pub-id><pub-id pub-id-type="pmid">11405803</pub-id>
</element-citation><mixed-citation id="mc-CR91" publication-type="journal">Lawn ND, Fletcher DD, Henderson RD, Wolter TD, Wijdicks EF. Anticipating mechanical ventilation in Guillain-Barr&#x000e9; syndrome. Arch Neurol. 2001;58(6):893&#x02013;8.<pub-id pub-id-type="pmid">11405803</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name><surname>Kannan Kanikannan</surname><given-names>MA</given-names></name><name><surname>Durga</surname><given-names>P</given-names></name><name><surname>Venigalla</surname><given-names>NK</given-names></name><name><surname>Kandadai</surname><given-names>RM</given-names></name><name><surname>Jabeen</surname><given-names>SA</given-names></name><name><surname>Borgohain</surname><given-names>R</given-names></name></person-group><article-title>Simple bedside predictors of mechanical ventilation in patients with Guillain-Barre syndrome</article-title><source>J Crit Care</source><year>2014</year><volume>29</volume><issue>2</issue><fpage>219</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.jcrc.2013.10.026</pub-id><pub-id pub-id-type="pmid">24378177</pub-id>
</element-citation><mixed-citation id="mc-CR92" publication-type="journal">Kannan Kanikannan MA, Durga P, Venigalla NK, Kandadai RM, Jabeen SA, Borgohain R. Simple bedside predictors of mechanical ventilation in patients with Guillain-Barre syndrome. J Crit Care. 2014;29(2):219&#x02013;23.<pub-id pub-id-type="pmid">24378177</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>C</given-names></name><name><surname>Baker</surname><given-names>T</given-names></name><name><surname>Subramaniam</surname><given-names>A</given-names></name></person-group><article-title>Predictors of respiratory failure in patients with Guillain-Barr&#x000e9; syndrome: a systematic review and meta-analysis</article-title><source>Med J Aust</source><year>2018</year><volume>208</volume><issue>4</issue><fpage>181</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.5694/mja17.00552</pub-id><pub-id pub-id-type="pmid">29490222</pub-id>
</element-citation><mixed-citation id="mc-CR93" publication-type="journal">Green C, Baker T, Subramaniam A. Predictors of respiratory failure in patients with Guillain-Barr&#x000e9; syndrome: a systematic review and meta-analysis. Med J Aust. 2018;208(4):181&#x02013;8.<pub-id pub-id-type="pmid">29490222</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name><surname>Melone</surname><given-names>MA</given-names></name><name><surname>Heming</surname><given-names>N</given-names></name><name><surname>Meng</surname><given-names>P</given-names></name><name><surname>Mompoint</surname><given-names>D</given-names></name><name><surname>Aboab</surname><given-names>J</given-names></name><name><surname>Clair</surname><given-names>B</given-names></name><etal/></person-group><article-title>Early mechanical ventilation in patients with Guillain-Barr&#x000e9; syndrome at high risk of respiratory failure: a randomized trial</article-title><source>Ann Intensive Care</source><year>2020</year><volume>10</volume><issue>1</issue><fpage>128</fpage><pub-id pub-id-type="doi">10.1186/s13613-020-00742-z</pub-id><pub-id pub-id-type="pmid">32997260</pub-id>
</element-citation><mixed-citation id="mc-CR94" publication-type="journal">Melone MA, Heming N, Meng P, Mompoint D, Aboab J, Clair B, et al. Early mechanical ventilation in patients with Guillain-Barr&#x000e9; syndrome at high risk of respiratory failure: a randomized trial. Ann Intensive Care. 2020;10(1):128.<pub-id pub-id-type="pmid">32997260</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name><surname>Sharshar</surname><given-names>T</given-names></name><name><surname>Chevret</surname><given-names>S</given-names></name><name><surname>Bourdain</surname><given-names>F</given-names></name><name><surname>Rapha&#x000eb;l</surname><given-names>JC</given-names></name></person-group><article-title>French cooperative group on plasma exchange in Guillain-Barr&#x000e9; syndrome. Early predictors of mechanical ventilation in Guillain-Barr&#x000e9; syndrome</article-title><source>Crit Care Med</source><year>2003</year><volume>31</volume><issue>1</issue><fpage>278</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1097/00003246-200301000-00044</pub-id><pub-id pub-id-type="pmid">12545029</pub-id>
</element-citation><mixed-citation id="mc-CR95" publication-type="journal">Sharshar T, Chevret S, Bourdain F, Rapha&#x000eb;l JC. French cooperative group on plasma exchange in Guillain-Barr&#x000e9; syndrome. Early predictors of mechanical ventilation in Guillain-Barr&#x000e9; syndrome. Crit Care Med. 2003;31(1):278&#x02013;83.<pub-id pub-id-type="pmid">12545029</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name><surname>Walgaard</surname><given-names>C</given-names></name><name><surname>Lingsma</surname><given-names>HF</given-names></name><name><surname>Ruts</surname><given-names>L</given-names></name><name><surname>Drenthen</surname><given-names>J</given-names></name><name><surname>van Koningsveld</surname><given-names>R</given-names></name><name><surname>Garssen</surname><given-names>MJP</given-names></name><etal/></person-group><article-title>Prediction of respiratory insufficiency in Guillain-Barr&#x000e9; syndrome</article-title><source>Ann Neurol</source><year>2010</year><volume>67</volume><issue>6</issue><fpage>781</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1002/ana.21976</pub-id><pub-id pub-id-type="pmid">20517939</pub-id>
</element-citation><mixed-citation id="mc-CR96" publication-type="journal">Walgaard C, Lingsma HF, Ruts L, Drenthen J, van Koningsveld R, Garssen MJP, et al. Prediction of respiratory insufficiency in Guillain-Barr&#x000e9; syndrome. Ann Neurol. 2010;67(6):781&#x02013;7.<pub-id pub-id-type="pmid">20517939</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name><surname>Luijten</surname><given-names>LWG</given-names></name><name><surname>Doets</surname><given-names>AY</given-names></name><name><surname>Arends</surname><given-names>S</given-names></name><name><surname>Dimachkie</surname><given-names>MM</given-names></name><name><surname>Gorson</surname><given-names>KC</given-names></name><name><surname>Islam</surname><given-names>B</given-names></name><etal/></person-group><article-title>Modified Erasmus GBS respiratory insufficiency score: a simplified clinical tool to predict the risk of mechanical ventilation in Guillain-Barr&#x000e9; syndrome</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2023</year><volume>94</volume><issue>4</issue><fpage>300</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2022-329937</pub-id><pub-id pub-id-type="pmid">36428088</pub-id>
</element-citation><mixed-citation id="mc-CR97" publication-type="journal">Luijten LWG, Doets AY, Arends S, Dimachkie MM, Gorson KC, Islam B, et al. Modified Erasmus GBS respiratory insufficiency score: a simplified clinical tool to predict the risk of mechanical ventilation in Guillain-Barr&#x000e9; syndrome. J Neurol Neurosurg Psychiatry. 2023;94(4):300&#x02013;8.<pub-id pub-id-type="pmid">36428088</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name><surname>Doets</surname><given-names>AY</given-names></name><name><surname>Walgaard</surname><given-names>C</given-names></name><name><surname>Lingsma</surname><given-names>HF</given-names></name><name><surname>Islam</surname><given-names>B</given-names></name><name><surname>Papri</surname><given-names>N</given-names></name><name><surname>Yamagishi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>International validation of the Erasmus Guillain-Barr&#x000e9; syndrome respiratory insufficiency score</article-title><source>Ann Neurol</source><year>2022</year><volume>91</volume><issue>4</issue><fpage>521</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1002/ana.26312</pub-id><pub-id pub-id-type="pmid">35106830</pub-id>
</element-citation><mixed-citation id="mc-CR98" publication-type="journal">Doets AY, Walgaard C, Lingsma HF, Islam B, Papri N, Yamagishi Y, et al. International validation of the Erasmus Guillain-Barr&#x000e9; syndrome respiratory insufficiency score. Ann Neurol. 2022;91(4):521&#x02013;31.<pub-id pub-id-type="pmid">35106830</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name><surname>Durand</surname><given-names>MC</given-names></name><name><surname>Porcher</surname><given-names>R</given-names></name><name><surname>Orlikowski</surname><given-names>D</given-names></name><name><surname>Aboab</surname><given-names>J</given-names></name><name><surname>Devaux</surname><given-names>C</given-names></name><name><surname>Clair</surname><given-names>B</given-names></name><etal/></person-group><article-title>Clinical and electrophysiological predictors of respiratory failure in Guillain-Barr&#x000e9; syndrome: a prospective study</article-title><source>Lancet Neurol</source><year>2006</year><volume>5</volume><issue>12</issue><fpage>1021</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(06)70603-2</pub-id><pub-id pub-id-type="pmid">17110282</pub-id>
</element-citation><mixed-citation id="mc-CR99" publication-type="journal">Durand MC, Porcher R, Orlikowski D, Aboab J, Devaux C, Clair B, et al. Clinical and electrophysiological predictors of respiratory failure in Guillain-Barr&#x000e9; syndrome: a prospective study. Lancet Neurol. 2006;5(12):1021&#x02013;8.<pub-id pub-id-type="pmid">17110282</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name><surname>Orlikowski</surname><given-names>D</given-names></name><name><surname>Prigent</surname><given-names>H</given-names></name><name><surname>Sharshar</surname><given-names>T</given-names></name><name><surname>Lofaso</surname><given-names>F</given-names></name><name><surname>Raphael</surname><given-names>JC</given-names></name></person-group><article-title>Respiratory dysfunction in Guillain-Barr&#x000e9; syndrome</article-title><source>Neurocrit Care</source><year>2004</year><volume>1</volume><issue>4</issue><fpage>415</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1385/NCC:1:4:415</pub-id><pub-id pub-id-type="pmid">16174943</pub-id>
</element-citation><mixed-citation id="mc-CR100" publication-type="journal">Orlikowski D, Prigent H, Sharshar T, Lofaso F, Raphael JC. Respiratory dysfunction in Guillain-Barr&#x000e9; syndrome. Neurocrit Care. 2004;1(4):415&#x02013;22.<pub-id pub-id-type="pmid">16174943</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name><surname>Chevrolet</surname><given-names>JC</given-names></name><name><surname>Del&#x000e9;amont</surname><given-names>P</given-names></name></person-group><article-title>Repeated vital capacity measurements as predictive parameters for mechanical ventilation need and weaning success in the Guillain-Barr&#x000e9; syndrome</article-title><source>Am Rev Respir Dis</source><year>1991</year><volume>144</volume><issue>4</issue><fpage>814</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1164/ajrccm/144.4.814</pub-id><pub-id pub-id-type="pmid">1928954</pub-id>
</element-citation><mixed-citation id="mc-CR101" publication-type="journal">Chevrolet JC, Del&#x000e9;amont P. Repeated vital capacity measurements as predictive parameters for mechanical ventilation need and weaning success in the Guillain-Barr&#x000e9; syndrome. Am Rev Respir Dis. 1991;144(4):814&#x02013;8.<pub-id pub-id-type="pmid">1928954</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name><surname>Kalita</surname><given-names>J</given-names></name><name><surname>Kumar</surname><given-names>M</given-names></name><name><surname>Misra</surname><given-names>UK</given-names></name></person-group><article-title>Serial single breath count is a reliable tool for monitoring respiratory functions in Guillain-Barr&#x000e9; syndrome</article-title><source>J Clin Neurosci</source><year>2020</year><volume>72</volume><fpage>50</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.jocn.2020.01.032</pub-id><pub-id pub-id-type="pmid">31982274</pub-id>
</element-citation><mixed-citation id="mc-CR102" publication-type="journal">Kalita J, Kumar M, Misra UK. Serial single breath count is a reliable tool for monitoring respiratory functions in Guillain-Barr&#x000e9; syndrome. J Clin Neurosci. 2020;72:50&#x02013;6.<pub-id pub-id-type="pmid">31982274</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name><surname>Fourrier</surname><given-names>F</given-names></name><name><surname>Robriquet</surname><given-names>L</given-names></name><name><surname>Hurtevent</surname><given-names>JF</given-names></name><name><surname>Spagnolo</surname><given-names>S</given-names></name></person-group><article-title>A simple functional marker to predict the need for prolonged mechanical ventilation in patients with Guillain-Barr&#x000e9; syndrome</article-title><source>Crit Care</source><year>2011</year><volume>15</volume><issue>1</issue><fpage>R65</fpage><pub-id pub-id-type="doi">10.1186/cc10043</pub-id><pub-id pub-id-type="pmid">21338488</pub-id>
</element-citation><mixed-citation id="mc-CR103" publication-type="journal">Fourrier F, Robriquet L, Hurtevent JF, Spagnolo S. A simple functional marker to predict the need for prolonged mechanical ventilation in patients with Guillain-Barr&#x000e9; syndrome. Crit Care. 2011;15(1):R65.<pub-id pub-id-type="pmid">21338488</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name><surname>Lawn</surname><given-names>ND</given-names></name><name><surname>Wijdicks</surname><given-names>EF</given-names></name></person-group><article-title>Tracheostomy in Guillain-Barr&#x000e9; syndrome</article-title><source>Muscle Nerve</source><year>1999</year><volume>22</volume><issue>8</issue><fpage>1058</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-4598(199908)22:8&#x0003c;1058::AID-MUS8&#x0003e;3.0.CO;2-G</pub-id><pub-id pub-id-type="pmid">10417787</pub-id>
</element-citation><mixed-citation id="mc-CR104" publication-type="journal">Lawn ND, Wijdicks EF. Tracheostomy in Guillain-Barr&#x000e9; syndrome. Muscle Nerve. 1999;22(8):1058&#x02013;62.<pub-id pub-id-type="pmid">10417787</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name><surname>Schr&#x000f6;der</surname><given-names>JB</given-names></name><name><surname>Marian</surname><given-names>T</given-names></name><name><surname>Muhle</surname><given-names>P</given-names></name><name><surname>Claus</surname><given-names>I</given-names></name><name><surname>Thomas</surname><given-names>C</given-names></name><name><surname>Ruck</surname><given-names>T</given-names></name><etal/></person-group><article-title>Intubation, tracheostomy, and decannulation in patients with Guillain-Barr&#x000e9;-syndrome-does dysphagia matter?</article-title><source>Muscle Nerve</source><year>2019</year><volume>59</volume><issue>2</issue><fpage>194</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1002/mus.26377</pub-id><pub-id pub-id-type="pmid">30390307</pub-id>
</element-citation><mixed-citation id="mc-CR105" publication-type="journal">Schr&#x000f6;der JB, Marian T, Muhle P, Claus I, Thomas C, Ruck T, et al. Intubation, tracheostomy, and decannulation in patients with Guillain-Barr&#x000e9;-syndrome-does dysphagia matter? Muscle Nerve. 2019;59(2):194&#x02013;200.<pub-id pub-id-type="pmid">30390307</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name><surname>Galassi</surname><given-names>G</given-names></name><name><surname>Mazzoli</surname><given-names>M</given-names></name><name><surname>Ariatti</surname><given-names>A</given-names></name><name><surname>Bedin</surname><given-names>R</given-names></name><name><surname>Marzullo</surname><given-names>D</given-names></name><name><surname>Bastia</surname><given-names>E</given-names></name><etal/></person-group><article-title>Predictors of respiratory failure in Guillain-Barr&#x000e9; syndrome: a 22 year cohort study from a single Italian centre</article-title><source>Eur J Neurol</source><year>2024</year><volume>31</volume><issue>1</issue><fpage>e16090</fpage><pub-id pub-id-type="doi">10.1111/ene.16090</pub-id><pub-id pub-id-type="pmid">37823704</pub-id>
</element-citation><mixed-citation id="mc-CR106" publication-type="journal">Galassi G, Mazzoli M, Ariatti A, Bedin R, Marzullo D, Bastia E, et al. Predictors of respiratory failure in Guillain-Barr&#x000e9; syndrome: a 22 year cohort study from a single Italian centre. Eur J Neurol. 2024;31(1):e16090.<pub-id pub-id-type="pmid">37823704</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>MCF</given-names></name><name><surname>Murphy</surname><given-names>PB</given-names></name><name><surname>Hart</surname><given-names>N</given-names></name><name><surname>Evans</surname><given-names>MRB</given-names></name><name><surname>Spillane</surname><given-names>JE</given-names></name><name><surname>Howard</surname><given-names>RS</given-names></name></person-group><article-title>Prolonged ventilatory support for patients recovering from Guillain-Barr&#x000e9; syndrome</article-title><source>Neurol Clin Pract</source><year>2021</year><volume>11</volume><issue>1</issue><fpage>18</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1212/CPJ.0000000000000793</pub-id><pub-id pub-id-type="pmid">33968468</pub-id>
</element-citation><mixed-citation id="mc-CR107" publication-type="journal">Cheng MCF, Murphy PB, Hart N, Evans MRB, Spillane JE, Howard RS. Prolonged ventilatory support for patients recovering from Guillain-Barr&#x000e9; syndrome. Neurol Clin Pract. 2021;11(1):18&#x02013;24.<pub-id pub-id-type="pmid">33968468</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>TN</given-names></name><name><surname>Badjatia</surname><given-names>N</given-names></name><name><surname>Malhotra</surname><given-names>A</given-names></name><name><surname>Gibbons</surname><given-names>FK</given-names></name><name><surname>Qureshi</surname><given-names>MM</given-names></name><name><surname>Greenberg</surname><given-names>SA</given-names></name></person-group><article-title>Factors predicting extubation success in patients with Guillain-Barr&#x000e9; syndrome</article-title><source>Neurocrit Care</source><year>2006</year><volume>5</volume><issue>3</issue><fpage>230</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1385/NCC:5:3:230</pub-id><pub-id pub-id-type="pmid">17290095</pub-id>
</element-citation><mixed-citation id="mc-CR108" publication-type="journal">Nguyen TN, Badjatia N, Malhotra A, Gibbons FK, Qureshi MM, Greenberg SA. Factors predicting extubation success in patients with Guillain-Barr&#x000e9; syndrome. Neurocrit Care. 2006;5(3):230&#x02013;4.<pub-id pub-id-type="pmid">17290095</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><mixed-citation publication-type="other">Liu J, Wang LN, McNicol ED. Pharmacological treatment for pain in Guillain-Barr&#x000e9; syndrome. Cochrane Database Syst Rev. 2015;4CD009950.</mixed-citation></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name><surname>Gales</surname><given-names>A</given-names></name><name><surname>Chaaban</surname><given-names>B</given-names></name><name><surname>Husson</surname><given-names>H</given-names></name><name><surname>Le Guennec</surname><given-names>L</given-names></name><name><surname>Viala</surname><given-names>K</given-names></name><name><surname>Maisonobe</surname><given-names>T</given-names></name><etal/></person-group><article-title>Lidocaine-medicated plaster for treating acute autonomic and sensory neuropathy with erythromelalgia-like presentations</article-title><source>Rev Neurol (Paris)</source><year>2016</year><volume>172</volume><issue>6&#x02013;7</issue><fpage>399</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1016/j.neurol.2016.03.004</pub-id><pub-id pub-id-type="pmid">27158041</pub-id>
</element-citation><mixed-citation id="mc-CR110" publication-type="journal">Gales A, Chaaban B, Husson H, Le Guennec L, Viala K, Maisonobe T, et al. Lidocaine-medicated plaster for treating acute autonomic and sensory neuropathy with erythromelalgia-like presentations. Rev Neurol (Paris). 2016;172(6&#x02013;7):399&#x02013;400.<pub-id pub-id-type="pmid">27158041</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name><surname>Doets</surname><given-names>AY</given-names></name><name><surname>Hughes</surname><given-names>RA</given-names></name><name><surname>Brassington</surname><given-names>R</given-names></name><name><surname>Hadden</surname><given-names>RD</given-names></name><name><surname>Pritchard</surname><given-names>J</given-names></name></person-group><article-title>Pharmacological treatment other than corticosteroids, intravenous Immunoglobulin and plasma exchange for Guillain-Barr&#x000e9; syndrome</article-title><source>Cochrane Database Syst Rev</source><year>2020</year><volume>1</volume><fpage>CD008630</fpage><pub-id pub-id-type="pmid">31981368</pub-id>
</element-citation><mixed-citation id="mc-CR111" publication-type="journal">Doets AY, Hughes RA, Brassington R, Hadden RD, Pritchard J. Pharmacological treatment other than corticosteroids, intravenous Immunoglobulin and plasma exchange for Guillain-Barr&#x000e9; syndrome. Cochrane Database Syst Rev. 2020;1:CD008630.<pub-id pub-id-type="pmid">31981368</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><citation-alternatives><element-citation id="ec-CR112" publication-type="journal"><person-group person-group-type="author"><name><surname>Halstead</surname><given-names>SK</given-names></name><name><surname>Zitman</surname><given-names>FMP</given-names></name><name><surname>Humphreys</surname><given-names>PD</given-names></name><name><surname>Greenshields</surname><given-names>K</given-names></name><name><surname>Verschuuren</surname><given-names>JJ</given-names></name><name><surname>Jacobs</surname><given-names>BC</given-names></name><etal/></person-group><article-title>Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model</article-title><source>Brain</source><year>2008</year><volume>131</volume><issue>Pt 5</issue><fpage>1197</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1093/brain/awm316</pub-id><pub-id pub-id-type="pmid">18184663</pub-id>
</element-citation><mixed-citation id="mc-CR112" publication-type="journal">Halstead SK, Zitman FMP, Humphreys PD, Greenshields K, Verschuuren JJ, Jacobs BC, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain. 2008;131(Pt 5):1197&#x02013;208.<pub-id pub-id-type="pmid">18184663</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR113"><label>113.</label><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>AI</given-names></name><name><surname>Halstead</surname><given-names>SK</given-names></name><name><surname>Goodfellow</surname><given-names>JA</given-names></name><name><surname>Chavada</surname><given-names>G</given-names></name><name><surname>Mallik</surname><given-names>A</given-names></name><name><surname>Overell</surname><given-names>J</given-names></name><etal/></person-group><article-title>Inhibition of complement in Guillain-Barr&#x000e9; syndrome: the ICA-GBS study</article-title><source>J Peripher Nerv Syst</source><year>2017</year><volume>22</volume><issue>1</issue><fpage>4</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1111/jns.12194</pub-id><pub-id pub-id-type="pmid">27801990</pub-id>
</element-citation><mixed-citation id="mc-CR113" publication-type="journal">Davidson AI, Halstead SK, Goodfellow JA, Chavada G, Mallik A, Overell J, et al. Inhibition of complement in Guillain-Barr&#x000e9; syndrome: the ICA-GBS study. J Peripher Nerv Syst. 2017;22(1):4&#x02013;12.<pub-id pub-id-type="pmid">27801990</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name><surname>Misawa</surname><given-names>S</given-names></name><name><surname>Kuwabara</surname><given-names>S</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Yamaguchi</surname><given-names>N</given-names></name><name><surname>Nagashima</surname><given-names>K</given-names></name><name><surname>Katayama</surname><given-names>K</given-names></name><etal/></person-group><article-title>Safety and efficacy of Eculizumab in Guillain-Barr&#x000e9; syndrome: a multicentre, double-blind, randomised phase 2 trial</article-title><source>Lancet Neurol</source><year>2018</year><volume>17</volume><issue>6</issue><fpage>519</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(18)30114-5</pub-id><pub-id pub-id-type="pmid">29685815</pub-id>
</element-citation><mixed-citation id="mc-CR114" publication-type="journal">Misawa S, Kuwabara S, Sato Y, Yamaguchi N, Nagashima K, Katayama K, et al. Safety and efficacy of Eculizumab in Guillain-Barr&#x000e9; syndrome: a multicentre, double-blind, randomised phase 2 trial. Lancet Neurol. 2018;17(6):519&#x02013;29.<pub-id pub-id-type="pmid">29685815</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name><surname>Busl</surname><given-names>KM</given-names></name><name><surname>Fried</surname><given-names>H</given-names></name><name><surname>Muehlschlegel</surname><given-names>S</given-names></name><name><surname>Wartenberg</surname><given-names>KE</given-names></name><name><surname>Rajajee</surname><given-names>V</given-names></name><name><surname>Alexander</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Guidelines for neuroprognostication in adults with Guillain-Barr&#x000e9; syndrome</article-title><source>Neurocrit Care</source><year>2023</year><volume>38</volume><issue>3</issue><fpage>564</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1007/s12028-023-01707-3</pub-id><pub-id pub-id-type="pmid">36964442</pub-id>
</element-citation><mixed-citation id="mc-CR115" publication-type="journal">Busl KM, Fried H, Muehlschlegel S, Wartenberg KE, Rajajee V, Alexander SA, et al. Guidelines for neuroprognostication in adults with Guillain-Barr&#x000e9; syndrome. Neurocrit Care. 2023;38(3):564&#x02013;83.<pub-id pub-id-type="pmid">36964442</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>RG</given-names></name><name><surname>Peterson</surname><given-names>GW</given-names></name><name><surname>Daube</surname><given-names>JR</given-names></name><name><surname>Albers</surname><given-names>JW</given-names></name></person-group><article-title>Prognostic value of electrodiagnosis in Guillain-Barr&#x000e9; syndrome</article-title><source>Muscle Nerve</source><year>1988</year><volume>11</volume><issue>7</issue><fpage>769</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1002/mus.880110714</pub-id><pub-id pub-id-type="pmid">3405243</pub-id>
</element-citation><mixed-citation id="mc-CR116" publication-type="journal">Miller RG, Peterson GW, Daube JR, Albers JW. Prognostic value of electrodiagnosis in Guillain-Barr&#x000e9; syndrome. Muscle Nerve. 1988;11(7):769&#x02013;74.<pub-id pub-id-type="pmid">3405243</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117.</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name><surname>McKhann</surname><given-names>GM</given-names></name><name><surname>Griffin</surname><given-names>JW</given-names></name><name><surname>Cornblath</surname><given-names>DR</given-names></name><name><surname>Mellits</surname><given-names>ED</given-names></name><name><surname>Fisher</surname><given-names>RS</given-names></name><name><surname>Quaskey</surname><given-names>SA</given-names></name></person-group><article-title>Plasmapheresis and Guillain-Barr&#x000e9; syndrome: analysis of prognostic factors and the effect of plasmapheresis</article-title><source>Ann Neurol</source><year>1988</year><volume>23</volume><issue>4</issue><fpage>347</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1002/ana.410230406</pub-id><pub-id pub-id-type="pmid">3382169</pub-id>
</element-citation><mixed-citation id="mc-CR117" publication-type="journal">McKhann GM, Griffin JW, Cornblath DR, Mellits ED, Fisher RS, Quaskey SA. Plasmapheresis and Guillain-Barr&#x000e9; syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol. 1988;23(4):347&#x02013;53.<pub-id pub-id-type="pmid">3382169</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118.</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name><surname>Walgaard</surname><given-names>C</given-names></name><name><surname>Lingsma</surname><given-names>HF</given-names></name><name><surname>Ruts</surname><given-names>L</given-names></name><name><surname>van Doorn</surname><given-names>PA</given-names></name><name><surname>Steyerberg</surname><given-names>EW</given-names></name><name><surname>Jacobs</surname><given-names>BC</given-names></name></person-group><article-title>Early recognition of poor prognosis in Guillain-Barre syndrome</article-title><source>Neurology</source><year>2011</year><volume>76</volume><issue>11</issue><fpage>968</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3182104407</pub-id><pub-id pub-id-type="pmid">21403108</pub-id>
</element-citation><mixed-citation id="mc-CR118" publication-type="journal">Walgaard C, Lingsma HF, Ruts L, van Doorn PA, Steyerberg EW, Jacobs BC. Early recognition of poor prognosis in Guillain-Barre syndrome. Neurology. 2011;76(11):968&#x02013;75.<pub-id pub-id-type="pmid">21403108</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119.</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name><surname>Walgaard</surname><given-names>C</given-names></name><name><surname>Lingsma</surname><given-names>HF</given-names></name><name><surname>van Doorn</surname><given-names>PA</given-names></name><name><surname>van der Jagt</surname><given-names>M</given-names></name><name><surname>Steyerberg</surname><given-names>EW</given-names></name><name><surname>Jacobs</surname><given-names>BC</given-names></name></person-group><article-title>Tracheostomy or not: prediction of prolonged mechanical ventilation in Guillain-Barr&#x000e9; syndrome</article-title><source>Neurocrit Care</source><year>2017</year><volume>26</volume><issue>1</issue><fpage>6</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1007/s12028-016-0311-5</pub-id><pub-id pub-id-type="pmid">27538676</pub-id>
</element-citation><mixed-citation id="mc-CR119" publication-type="journal">Walgaard C, Lingsma HF, van Doorn PA, van der Jagt M, Steyerberg EW, Jacobs BC. Tracheostomy or not: prediction of prolonged mechanical ventilation in Guillain-Barr&#x000e9; syndrome. Neurocrit Care. 2017;26(1):6&#x02013;13.<pub-id pub-id-type="pmid">27538676</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120.</label><citation-alternatives><element-citation id="ec-CR120" publication-type="journal"><person-group person-group-type="author"><name><surname>Terayama</surname><given-names>A</given-names></name><name><surname>Kuwahara</surname><given-names>M</given-names></name><name><surname>Yoshikawa</surname><given-names>K</given-names></name><name><surname>Yamagishi</surname><given-names>Y</given-names></name><name><surname>Samukawa</surname><given-names>M</given-names></name><name><surname>Yamashita</surname><given-names>S</given-names></name><name><surname>Onishi</surname><given-names>K</given-names></name><name><surname>Nagano</surname><given-names>T</given-names></name><name><surname>Tatsumi</surname><given-names>C</given-names></name><name><surname>Ishii</surname><given-names>J</given-names></name><name><surname>Kawamoto</surname><given-names>M</given-names></name><name><surname>Tokashiki</surname><given-names>T</given-names></name><name><surname>Deguchi</surname><given-names>S</given-names></name><name><surname>Deguchi</surname><given-names>K</given-names></name><name><surname>Ishida</surname><given-names>A</given-names></name><name><surname>Baba</surname><given-names>Y</given-names></name><name><surname>Yamaguchi</surname><given-names>S</given-names></name><name><surname>Kusunoki</surname><given-names>S</given-names></name><name><surname>Nagai</surname><given-names>Y</given-names></name></person-group><article-title>Takotsubo cardiomyopathy in Guillain-Barr&#x000e9; syndrome</article-title><source>J Neurol</source><year>2024</year><volume>271</volume><issue>7</issue><fpage>4067</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1007/s00415-024-12295-3</pub-id><pub-id pub-id-type="pmid">38573364</pub-id>
</element-citation><mixed-citation id="mc-CR120" publication-type="journal">Terayama A, Kuwahara M, Yoshikawa K, Yamagishi Y, Samukawa M, Yamashita S, Onishi K, Nagano T, Tatsumi C, Ishii J, Kawamoto M, Tokashiki T, Deguchi S, Deguchi K, Ishida A, Baba Y, Yamaguchi S, Kusunoki S, Nagai Y. Takotsubo cardiomyopathy in Guillain-Barr&#x000e9; syndrome. J Neurol. 2024;271(7):4067&#x02013;74.<pub-id pub-id-type="pmid">38573364</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR121"><label>121.</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name><surname>Sharshar</surname><given-names>T</given-names></name><name><surname>Polito</surname><given-names>A</given-names></name><name><surname>Porcher</surname><given-names>R</given-names></name><name><surname>Merhbene</surname><given-names>T</given-names></name><name><surname>Blanc</surname><given-names>M</given-names></name><name><surname>Antona</surname><given-names>M</given-names></name><name><surname>Durand</surname><given-names>MC</given-names></name><name><surname>Friedman</surname><given-names>D</given-names></name><name><surname>Orlikowski</surname><given-names>D</given-names></name><name><surname>Annane</surname><given-names>D</given-names></name><name><surname>Marcadet</surname><given-names>MH</given-names></name></person-group><article-title>Relevance of anxiety in clinical practice of Guillain-Barre syndrome: a cohort study</article-title><source>BMJ Open</source><year>2012</year><volume>2</volume><issue>4</issue><fpage>e000893</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2012-000893</pub-id></element-citation><mixed-citation id="mc-CR121" publication-type="journal">Sharshar T, Polito A, Porcher R, Merhbene T, Blanc M, Antona M, Durand MC, Friedman D, Orlikowski D, Annane D, Marcadet MH. Relevance of anxiety in clinical practice of Guillain-Barre syndrome: a cohort study. BMJ Open. 2012;2(4):e000893.</mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name><surname>Polito</surname><given-names>A</given-names></name><name><surname>Polito</surname><given-names>A</given-names></name><name><surname>Bouchereau</surname><given-names>E</given-names></name><name><surname>Moneger</surname><given-names>G</given-names></name><name><surname>Ritzenthaler</surname><given-names>T</given-names></name><name><surname>Annane</surname><given-names>D</given-names></name><name><surname>Heming</surname><given-names>N</given-names></name><name><surname>Sharshar</surname><given-names>T</given-names></name></person-group><article-title>Dysglycemia and neurologic outcome in mechanically ventilated patients with Guillain-Barr&#x000e9; syndrome</article-title><source>Crit Care Med</source><year>2019</year><volume>47</volume><issue>3</issue><fpage>e227</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1097/CCM.0000000000003635</pub-id><pub-id pub-id-type="pmid">30585828</pub-id>
</element-citation><mixed-citation id="mc-CR122" publication-type="journal">Polito A, Polito A, Bouchereau E, Moneger G, Ritzenthaler T, Annane D, Heming N, Sharshar T. Dysglycemia and neurologic outcome in mechanically ventilated patients with Guillain-Barr&#x000e9; syndrome. Crit Care Med. 2019;47(3):e227&#x02013;33.<pub-id pub-id-type="pmid">30585828</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>F</given-names></name><name><surname>Amatya</surname><given-names>B</given-names></name></person-group><article-title>Rehabilitation interventions in patients with acute demyelinating inflammatory polyneuropathy: a systematic review</article-title><source>Eur J Phys Rehabil Med</source><year>2012</year><volume>48</volume><fpage>507</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">22820829</pub-id>
</element-citation><mixed-citation id="mc-CR123" publication-type="journal">Khan F, Amatya B. Rehabilitation interventions in patients with acute demyelinating inflammatory polyneuropathy: a systematic review. Eur J Phys Rehabil Med. 2012;48:507&#x02013;22.<pub-id pub-id-type="pmid">22820829</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124.</label><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name><surname>Simatos Arsenault</surname><given-names>N</given-names></name><name><surname>Vincent</surname><given-names>PO</given-names></name><name><surname>Yu</surname><given-names>BH</given-names></name><name><surname>Bastien</surname><given-names>R</given-names></name><name><surname>Sweeney</surname><given-names>A</given-names></name></person-group><article-title>Influence of exercise on patients with Guillain-Barr&#x000e9; syndrome: A systematic review</article-title><source>Physiother Can</source><year>2016</year><volume>68</volume><issue>4</issue><fpage>367</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.3138/ptc.2015-58</pub-id><pub-id pub-id-type="pmid">27904236</pub-id>
</element-citation><mixed-citation id="mc-CR124" publication-type="journal">Simatos Arsenault N, Vincent PO, Yu BH, Bastien R, Sweeney A. Influence of exercise on patients with Guillain-Barr&#x000e9; syndrome: A systematic review. Physiother Can. 2016;68(4):367&#x02013;76.<pub-id pub-id-type="pmid">27904236</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR125"><label>125.</label><citation-alternatives><element-citation id="ec-CR125" publication-type="journal"><person-group person-group-type="author"><name><surname>Kuwabara</surname><given-names>S</given-names></name><name><surname>Kusunoki</surname><given-names>S</given-names></name><name><surname>Kuwahara</surname><given-names>M</given-names></name><name><surname>Yamano</surname><given-names>Y</given-names></name><name><surname>Nishida</surname><given-names>Y</given-names></name><name><surname>Ishida</surname><given-names>H</given-names></name><name><surname>Kasuya</surname><given-names>T</given-names></name><name><surname>Kupperman</surname><given-names>E</given-names></name><name><surname>Lin</surname><given-names>Q</given-names></name><name><surname>Frick</surname><given-names>G</given-names></name><name><surname>Misawa</surname><given-names>S</given-names></name></person-group><article-title>Efficacy and safety of Eculizumab in Guillain-Barre syndrome: A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial</article-title><source>J Peripher Nerv Syst</source><year>2024</year><volume>29</volume><issue>3</issue><fpage>339</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1111/jns.12646</pub-id><pub-id pub-id-type="pmid">38987228</pub-id>
</element-citation><mixed-citation id="mc-CR125" publication-type="journal">Kuwabara S, Kusunoki S, Kuwahara M, Yamano Y, Nishida Y, Ishida H, Kasuya T, Kupperman E, Lin Q, Frick G, Misawa S. Efficacy and safety of Eculizumab in Guillain-Barre syndrome: A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial. J Peripher Nerv Syst. 2024;29(3):339&#x02013;49.<pub-id pub-id-type="pmid">38987228</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR126"><label>126.</label><citation-alternatives><element-citation id="ec-CR126" publication-type="journal"><person-group person-group-type="author"><name><surname>Melone</surname><given-names>MA</given-names></name><name><surname>Heming</surname><given-names>N</given-names></name><name><surname>Meng</surname><given-names>P</given-names></name><name><surname>Mompoint</surname><given-names>D</given-names></name><name><surname>Aboab</surname><given-names>J</given-names></name><name><surname>Clair</surname><given-names>B</given-names></name><name><surname>Salomon</surname><given-names>J</given-names></name><name><surname>Sharshar</surname><given-names>T</given-names></name><name><surname>Orlikowski</surname><given-names>D</given-names></name><name><surname>Chevret</surname><given-names>S</given-names></name><name><surname>Annane</surname><given-names>D</given-names></name></person-group><article-title>Early mechanical ventilation in patients with Guillain-Barr&#x000e9; syndrome at high risk of respiratory failure: a randomized trial</article-title><source>Ann Intensive Care</source><year>2020</year><volume>10</volume><issue>1</issue><fpage>128</fpage><pub-id pub-id-type="doi">10.1186/s13613-020-00742-z</pub-id><pub-id pub-id-type="pmid">32997260</pub-id>
</element-citation><mixed-citation id="mc-CR126" publication-type="journal">Melone MA, Heming N, Meng P, Mompoint D, Aboab J, Clair B, Salomon J, Sharshar T, Orlikowski D, Chevret S, Annane D. Early mechanical ventilation in patients with Guillain-Barr&#x000e9; syndrome at high risk of respiratory failure: a randomized trial. Ann Intensive Care. 2020;10(1):128.<pub-id pub-id-type="pmid">32997260</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR127"><label>127.</label><citation-alternatives><element-citation id="ec-CR127" publication-type="journal"><person-group person-group-type="author"><name><surname>Orlikowski</surname><given-names>D</given-names></name><name><surname>Sharshar</surname><given-names>T</given-names></name><name><surname>Porcher</surname><given-names>R</given-names></name><name><surname>Annane</surname><given-names>D</given-names></name><name><surname>Raphael</surname><given-names>JC</given-names></name><name><surname>Clair</surname><given-names>B</given-names></name></person-group><article-title>Prognosis and risk factors of early onset pneumonia in ventilated patients with Guillain-Barr&#x000e9; syndrome</article-title><source>Intensive Care Med</source><year>2006</year><volume>32</volume><issue>12</issue><fpage>1962</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s00134-006-0332-1</pub-id><pub-id pub-id-type="pmid">17019557</pub-id>
</element-citation><mixed-citation id="mc-CR127" publication-type="journal">Orlikowski D, Sharshar T, Porcher R, Annane D, Raphael JC, Clair B. Prognosis and risk factors of early onset pneumonia in ventilated patients with Guillain-Barr&#x000e9; syndrome. Intensive Care Med. 2006;32(12):1962&#x02013;9.<pub-id pub-id-type="pmid">17019557</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR128"><label>128.</label><mixed-citation publication-type="other">Dhar R, Stitt L, Hahn AF. (2008) The morbidity and outcome of patients with Guillain-Barr&#x000e9; syndrome admitted to the intensive care unit. J Neurol Sci 2008, 264:121&#x02013;128.</mixed-citation></ref><ref id="CR129"><label>129.</label><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name><surname>Bernardes Neto</surname><given-names>SCG</given-names></name><name><surname>Torres-Castro</surname><given-names>R</given-names></name><name><surname>Lima</surname><given-names>&#x000cd;</given-names></name><name><surname>Resqueti</surname><given-names>VR</given-names></name><name><surname>Fregonezi</surname><given-names>GAF</given-names></name></person-group><article-title>Weaning from mechanical ventilation in people with neuromuscular disease: a systematic review</article-title><source>BMJ Open</source><year>2021</year><volume>11</volume><issue>9</issue><fpage>e047449</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2020-047449</pub-id></element-citation><mixed-citation id="mc-CR129" publication-type="journal">Bernardes Neto SCG, Torres-Castro R, Lima &#x000cd;, Resqueti VR, Fregonezi GAF. Weaning from mechanical ventilation in people with neuromuscular disease: a systematic review. BMJ Open. 2021;11(9):e047449.</mixed-citation></citation-alternatives></ref><ref id="CR130"><label>130.</label><mixed-citation publication-type="other">Orlikowski D, Prigent H, Rapha&#x000eb;l JC, Sharshar T. Acute respiratory failure in Guillain-Barr&#x000e9; syndrome and myasthenia gravis. R&#x000e9;animation 2005 14(2):118&#x02013;125.</mixed-citation></ref><ref id="CR131"><label>131.</label><citation-alternatives><element-citation id="ec-CR131" publication-type="journal"><person-group person-group-type="author"><name><surname>Mazeraud</surname><given-names>A</given-names></name><name><surname>Sivanandamoorthy</surname><given-names>S</given-names></name><name><surname>Mancusi</surname><given-names>R</given-names></name><name><surname>Clair</surname><given-names>B</given-names></name><name><surname>Friedman</surname><given-names>D</given-names></name><name><surname>Fadel</surname><given-names>F</given-names></name><name><surname>Maxime</surname><given-names>V</given-names></name><name><surname>Legouy</surname><given-names>C</given-names></name><name><surname>Orlikowski</surname><given-names>D</given-names></name><name><surname>Sharshar</surname><given-names>T</given-names></name><name><surname>Heming</surname><given-names>N</given-names></name><name><surname>Annane</surname><given-names>D</given-names></name></person-group><article-title>Weaning from mechanical ventilation during myasthenic crisis, a monocentric retrospective study</article-title><source>Sci Rep</source><year>2024</year><volume>14</volume><issue>1</issue><fpage>19523</fpage><pub-id pub-id-type="doi">10.1038/s41598-024-70373-y</pub-id><pub-id pub-id-type="pmid">39174610</pub-id>
</element-citation><mixed-citation id="mc-CR131" publication-type="journal">Mazeraud A, Sivanandamoorthy S, Mancusi R, Clair B, Friedman D, Fadel F, Maxime V, Legouy C, Orlikowski D, Sharshar T, Heming N, Annane D. Weaning from mechanical ventilation during myasthenic crisis, a monocentric retrospective study. Sci Rep. 2024;14(1):19523.<pub-id pub-id-type="pmid">39174610</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR132"><label>132.</label><citation-alternatives><element-citation id="ec-CR132" publication-type="journal"><person-group person-group-type="author"><name><surname>Mezidi</surname><given-names>M</given-names></name><name><surname>Yonis</surname><given-names>H</given-names></name><name><surname>Chauvelot</surname><given-names>L</given-names></name><name><surname>Deniel</surname><given-names>G</given-names></name><name><surname>Dhelft</surname><given-names>F</given-names></name><name><surname>Gaillet</surname><given-names>M</given-names></name><name><surname>Noirot</surname><given-names>I</given-names></name><name><surname>Folliet</surname><given-names>L</given-names></name><name><surname>Chabert</surname><given-names>P</given-names></name><name><surname>David</surname><given-names>G</given-names></name><name><surname>Danjou</surname><given-names>W</given-names></name><name><surname>Baboi</surname><given-names>L</given-names></name><name><surname>Bettinger</surname><given-names>C</given-names></name><name><surname>Bernon</surname><given-names>P</given-names></name><name><surname>Girard</surname><given-names>M</given-names></name><name><surname>Provoost</surname><given-names>J</given-names></name><name><surname>Bazzani</surname><given-names>A</given-names></name><name><surname>Bitker</surname><given-names>L</given-names></name><name><surname>Richard</surname><given-names>JC</given-names></name></person-group><article-title>Spontaneous breathing trial with pressure support on positive end-expiratory pressure and extensive use of non-invasive ventilation versus T-piece in difficult-to-wean patients from mechanical ventilation: a randomized controlled trial</article-title><source>Ann Intensive Care</source><year>2024</year><volume>14</volume><issue>1</issue><fpage>59</fpage><pub-id pub-id-type="doi">10.1186/s13613-024-01290-6</pub-id><pub-id pub-id-type="pmid">38630372</pub-id>
</element-citation><mixed-citation id="mc-CR132" publication-type="journal">Mezidi M, Yonis H, Chauvelot L, Deniel G, Dhelft F, Gaillet M, Noirot I, Folliet L, Chabert P, David G, Danjou W, Baboi L, Bettinger C, Bernon P, Girard M, Provoost J, Bazzani A, Bitker L, Richard JC. Spontaneous breathing trial with pressure support on positive end-expiratory pressure and extensive use of non-invasive ventilation versus T-piece in difficult-to-wean patients from mechanical ventilation: a randomized controlled trial. Ann Intensive Care. 2024;14(1):59.<pub-id pub-id-type="pmid">38630372</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR133"><label>133.</label><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name><surname>Egger</surname><given-names>M</given-names></name><name><surname>Finsterh&#x000f6;lzl</surname><given-names>M</given-names></name><name><surname>Farabegoli</surname><given-names>D</given-names></name><name><surname>Wippenbeck</surname><given-names>F</given-names></name><name><surname>Schlutt</surname><given-names>M</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>F</given-names></name><name><surname>Huge</surname><given-names>V</given-names></name><name><surname>Jahn</surname><given-names>K</given-names></name><name><surname>Bergmann</surname><given-names>J</given-names></name></person-group><article-title>Comprehensive assessment and progression of health status during neurorehabilitation in survivors of critical illness: a prospective cohortstudy</article-title><source>Ann Intensive Care</source><year>2024</year><volume>14</volume><issue>1</issue><fpage>175</fpage><pub-id pub-id-type="doi">10.1186/s13613-024-01396-x</pub-id><pub-id pub-id-type="pmid">39589665</pub-id>
</element-citation><mixed-citation id="mc-CR133" publication-type="journal">Egger M, Finsterh&#x000f6;lzl M, Farabegoli D, Wippenbeck F, Schlutt M, M&#x000fc;ller F, Huge V, Jahn K, Bergmann J. Comprehensive assessment and progression of health status during neurorehabilitation in survivors of critical illness: a prospective cohortstudy. Ann Intensive Care. 2024;14(1):175.<pub-id pub-id-type="pmid">39589665</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>